Journal of Hepatology

The immunological system in hemochromatosis
pp. 1-7(7)
Authors: de Sousa M.; Porto G.

Iron, oxidative stress and liver fibrogenesis
pp. 8-13(6)
Author: Pietrangelo A.

Hemochromatosis after the gene discovery: revisiting the diagnostic strategy
pp. 14-18(5)
Authors: Brissot P.; Moirand R.; Guyader D.; Loreal O.; Turlin B.; Deugnier Y.

Iron overload in viral and alcoholic liver disease
pp. 19-20(2)
Author: Adams P.C.

Iron and neoplasia
pp. 21-25(5)
Authors: Deugnier Y.; Turlin B.; Loreal O.

Revisiting various iron overload syndromes after the haemochromatosis gene discovery
pp. 26-27(2)
Author: Worwood M.

Wilson disease in 1998: genetic, diagnostic and therapeutic aspects
pp. 28-36(9)
Authors: Gollan J.L.; Gollan T.J.

Gene therapy of hepatocellular carcinoma (HCC) using adenovirus expressing interleukin-12 (ADCMVIL-12) and thymidin kinase (ADCMVTK)
pp. 41-41(1)
Authors: Drozdzik M.; Oian C.; Xie X.; Bilbao R.; Sun Y.; Mazzolini G.; Prieto J.

Gene therapy for rat hepatocarcinoma (HCC) using intratumorous injection of recombinant adenoviruses carrying herpes simplex virus thymidine kinase gene (HSVTK)
pp. 41-41(1)
Authors: Gerolami R.; Lewin M.; Bralet M.; Clement O.; Frija F.; Tran P.; Brechot C.

Characterisation of hepatocyte growth factor gene promoter
pp. 41-41(1)
Authors: Bradley L.; Harrison P.

Transport properties of the canalicular bile salt transporter or sister of P-glycoprotein
pp. 41-41(1)
Authors: Stieger B.; St. Pierre M.V.; Meier P.J.

The SPGP gene, encoding the canalicular bile acid transporting protein SPGP/cBST, is not expressed in a subgroup of patients with progressive familial intrahepatic cholestasis (PFIC-2)
pp. 42-42(1)
Authors: Jansen P.; Hooiveld G.; Koning H.; van Goor H.; Gouw A.; Kuipers F.; Bijleveld C.; Slooff M.; Muller M.

Incidence and predictive factors of severe HCV recurrence after liver transplantation
pp. 42-42(1)
Authors: Rimola A.; Restrepo J.; Quinto L.; Sanchez-Tapias J.; Navasa M.; Cirera I.; Grande L.; Visa J.; Rodes J.

Lamivudine and intron a combination treatment in patients with chronic hepatitis B infection
pp. 43-43(1)
Authors: Heathcote J.; Schalm S.; Cianciara J.; Farrell G.; Feinmann V.; Shermann M.; Dhillon A.; Moorat A.; Gray D.

Lamivudine therapy in patients with anti HBe positive chronic hepatitis B; end of treatment analysis
pp. 43-43(1)
Authors: Tassopoulos N.; Volpes R.; Pastore G.; Heathcote J.; Buti M.; Goldin R.; Hawley S.; Gray D.

Treatment of woodchuck hepatitis virus (WHV) infection with recombinant defective adenoviruses
pp. 43-43(1)
Authors: Ruiz J.; Sanchez de la Rosa R.; Garcia R.; Lasarte J.J.; Hervas-Stubbs S.; Sola J.J.; Prieto J.

Response of T cells from HCV reinfected grafts after LTX resembles that of T cells from peripheral blood in acute hepatitis C
pp. 43-43(1)
Authors: Schirren C.; Jung M.; Worzfeld T.; Mamin M.; Gerlach J.; Gruner N.; Hoffmann R.; Diepolder H.; Zachoval R.; Houghton M.; Pape G.

The stage of chronic hepatitis C and the type of response to interferon therapy are not related with hepatitis C virus (HCV) genotype 1b quasispecies complexity
pp. 44-44(1)
Authors: Lopez-Labrador F.; Gimenez-Barcons M.; Ampurdanes S.; Sanchez-Tapias J.; Rodes J.; Saiz J.

Recurrence of hepatitis C virus after loss of virus specific CD4+ T cell response in acute hepatitis C
pp. 44-44(1)
Authors: Gerlach J.T.; Diepolder H.M.; Gruner N.H.; Jung M.C.; Zachoval R.; Hoffmann R.; Schirren C.A.; Schraut W.; Santantonio T.; Houghton M.; Pape G.R.

Evidence of reduced effectiveness of an otherwise increased endogenous dopaminergic activity in compensated cirrhosis
pp. 45-45(1)
Authors: Sansoe G.; Ferrari A.; Baraldi E.; Castellana C.; Terranova G.; Ghidoni M.; Villa E.; Manenti F.

Hepatic blood flow and splanchnic oxygen consumption in patients with hepatic encephalopathy before and after high-volume plasmapheresis
pp. 45-45(1)
Authors: Clemmesen J.; Larsen F.; Hansen B.; Ott P.

Intravenous albumin infusion prevents renal impairment (RI) and improves hospital survival in patients with spontaneous bacterial peritonitis (SBP)
pp. 45-45(1)
Authors: Sort P.; Navasa M.

Critical role of distal tubular handling of sodium in the regulation of extracellular fluid volume in compensated cirrhosis
pp. 45-45(1)
Authors: Sansoe G.; Ferrari A.; Baraldi E.; Castellana C.; Ghidoni M.; Villa E.; Manenti F.

Effects of nitric oxide (NO)-donors on activated human hepatic stellate cells (HSC): cellular basis for the treatment of portal hypertension
pp. 46-46(1)
Authors: DeFranco R.M.S.; Caligiuri A.; Failli P.; Gentilini A.; Romanelli R.; Casini A.; Tosti-Guerra C.; Gentilini P.; Laffi G.; Pinzani M.

Connective tissue growth factor in human liver cirrhosis
pp. 46-46(1)
Authors: Abou-Shady M.; Friess H.; di Mola F.; Zimmermann A.; Baer H.; Buchler M.

Reduction of Kupffer cell-induced oxidant injury of the rat liver by atrial natriuretic peptide and cyclo-GMP receptor proteins
pp. 47-47(1)
Authors: Bilzer M.; Jaeschke H.; Vollmar A.M.; Paumgartner G.; Gerbes A.L.

Hepatic stellate cells become susceptible to fas-ligand induced apoptosis during transformation to myofibroblasts
pp. 47-47(1)
Authors: Gressner A.M.; Lahme B.; Roth S.; Gong W.R.

Antitumor effect of fibroblast engineered to express fas ligand (FasL) on hepatocellular carcinoma (HCC)
pp. 47-47(1)
Authors: Drozdzik M.; Oian C.; Lasarte J.; Prieto J.

CD95 ligand induced apoptosis as a mechanism of intrahepatic immunoregulation
pp. 47-47(1)
Authors: Muschen M.; Warskulat U.; Haussinger D.

Chronic HCV: viral kinetics and duration of therapy
pp. 48-48(1)
Authors: Bekkering F.C.; Brouwer J.T.; Elewaut A.; Schalm S.W.

Incidence, characteristics and clinical impact of lamivudine resistance in chronic hepatitis B
pp. 48-48(1)
Authors: Honkoop P.; de Man R.; Niesters H.; Schalm S.

NFB mediates LPS-induced expression of IL-6 and ICAM-1 in activated hepatic stellate cells, a process blocked by proteasome inhibitors
pp. 49-49(1)
Authors: Hellerbrand C.; Jobin C.; Licato L.L.; Sartor R.B.; Brenner D.A.

Hepatitis B virus X protein interacts with NF-KB inhibitors
pp. 49-49(1)
Authors: Sirma H.; Weil R.; Kremsdorf D.; Brechot C.; Israel A.

NF-KB is a potent inhibitor of TNF- induced apoptosis in human hepatoma cells
pp. 49-49(1)
Authors: Malek N.P.; Pluempe J.; Bock C.T.; Kubicka S.; Manns M.P.; Trautwein C.

Genetic and functional analysis of HBV pX mutants from HCC patients
pp. 49-49(1)
Authors: Pagano S.; Artini M.; Costanzo A.; Chirillo P.; Fulco M.; Almerighi C.; Balsano C.; Levrero M.

HBV variants create ''altered peptide ligands'' which results in altered CD4+ T-cell function
pp. 50-50(1)
Authors: Jung M.-C.; Gerlach J.T.; Santantonio T.; Diepolder H.; Wierenga E.; Gruner N.; Zachoval R.; Hoffmann R.; Southwood S.; Sette A.; Gunther S.; Will H.; Pape G.R.

Evidence for a new HBV protein encoded by a spliced RNA
pp. 50-50(1)
Authors: Soussan P.; Garreau F.; Rosmorduc O.; Zilberberg H.; Rahmoune N.A.; Nalpas B.; Brechot C.; Kremsdorf D.

Evidence for a transmissible factor in primary biliary cirrhosis (PBC)
pp. 51-51(1)
Authors: Joplin R.; Sadamoto T.; Wallace L.; Carman W.; Mason A.; Neuberger J.

Sclerosing cholangitis in childhood: an 18-year experience
pp. 51-51(1)
Authors: Gregorio G.; Karani J.; Portmann B.; Mieli-Vergani G.

Induction of cytotoxic lymphocytes against hepatitis C virus using a synthetic peptide from structural protein E1
pp. 51-51(1)
Authors: Casares N.; Lasarte J.; Lopez-Diaz de Cerio A.; Prieto J.; Borras-Cuesta F.

Maintenance of a virus specific helper T cell response 20 years after infection with one strain of HCV in healthy individuals
pp. 51-51(1)
Authors: Gerlach J.T.; Kullig U.; Gruner N.H.; Diepolder H.M.; Jung M.C.; Zachoval R.; Hoffmann R.; Schirren C.A.; Schraut W.; Porst H.; Pape G.R.

Redox-sensitive transcription factors NF-B and AP-1 are involved in the hepatic protection from ischemia-reperfusion injury (IRPI) by the atrial natriuretic peptide (ANP)
pp. 52-52(1)
Authors: Kiemer A.K.; Bilzer M.; Vollmar A.M.; Gerbes A.L.

Intra-graft proliferation of naive and memory T lymphocytes during hepatic allograft rejection
pp. 52-52(1)
Authors: Dollinger M.; Howie S.; Plevris J.; Hayes P.; Harrison D.

Hepatitis C virus (HCV) genotype 1B infection is associated with a high incidence of graft cirrhosis after liver transplantation (OLT)
pp. 53-53(1)
Authors: Prieto M.; Rayon M.; Berenguer M.; Cordoba J.; Carrasco D.; Olaso V.; Mir J.; Berenguer J.

Impact of gender matching on paediatric liver transplantation (LT)
pp. 53-53(1)
Authors: Francavilla R.; Hadzic N.; Heaton N.; Rela M.; Cheeseman P.; Baker A.; Dhawan A.; Mieli-Vergani G.

Prednisone is unnecessary as routine treatment after liver transplantation (OLT)
pp. 53-53(1)
Authors: Tisone G.; Angelico M.; Palmieri G.; Pisani F.; Baiocchi L.; Anselmo A.; Negrini S.; Orlando G.; Vennarecci G.; Casciani C.U.

Levels of soluble fas ligand, hepatocyte growth factor and proinflammatory cytokines in children with fulminant hepatic failure
pp. 53-53(1)
Authors: Hussain M.; Kallas M.; Yagita H.; Mieli-Vergani G.; Vergani D.

Reversed ammonia kinetics in acute liver failure: splanchnic release and cerebral uptake. Related to cerebral herniation ?
pp. 54-54(1)
Authors: Clemmesen J.; Larsen F.; Hansen B.; Ott P.

High rate of Ito cells activation, hepatocellular apoptosis and regeneration in transplanted liver: clues to the early appearance of cirrhosis?
pp. 54-54(1)
Authors: Ballardini G.; Ghetti S.; Groff P.; Grassi A.; Lari F.; Zauli D.; De Raffele E.; Temmolo R.; Cavallari A.; Bianchi F.

Venoocclusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilection
pp. 54-54(1)
Authors: Sebagh M.; Debette M.; Samuel D.; Emile J.; Bismuth H.; Reynes M.

Excellent long-term survival following liver transplantation in primary sclerosing cholangitis patients
pp. 54-54(1)
Authors: Graziadei I.; Wiesner R.; Marotta P.; Porayko M.; Hay J.; LaRusso N.; Krom R.

Cellular and humoral immune responses in mice after genetic immunization against the nonstructural proteins of hepatitis C virus
pp. 55-55(1)
Authors: Encke J.; Geissler M.; zu Putlitz J.; Wands J.R.

Evidence for reduced rates of quasispecies diversification during combination interferon plus ribavirin therapy for chronic hepatitis C
pp. 55-55(1)
Authors: Gerotto M.; Sullivan D.; Pontisso P.; Chemello L.; Alberti A.; Gretch D.

Haemochromatosis CYS282TYR and HIS63ASP mutations in hepatitis C virus infection: correlation with ALT and iron serum levels
pp. 55-55(1)
Authors: Martinelli A.; Franco R.; Villanova M.; Filho A.A.; Figueiredo J.; Covas D.; Passos A.; Secaf M.; Rodrigues S.; Tavella M.; Zucoloto S.; Zago M.

Alcohol intake, even moderate, induces increased histological activity and fibrosis in patients with chronic active hepatitis C
pp. 55-55(1)
Authors: Lonjon I.; Hezode C.; Roudot-Thoraval F.; Bastie A.; Pawlotsky J.; Zafrani E.S.; Dhumeaux D.

Hepatitis B virus E antigen but not HBV core is presented to specific CD4+ T cells via the endogenous antigen processing pathway
pp. 56-56(1)
Authors: Diepolder H.M.; Ries G.; Jung M.-C.; Schlicht H.-J.; Gerlach J.-T.; Gruner N.; Hofschneider P.H.; Caselmann W.H.; Pape G.R.

Overexpression of the hepatitis B virus X gene in liver cells is associated with apoptosis
pp. 56-56(1)
Authors: Pollicino T.; Lecoeur H.; Terradillos O.; Tripodi M.; Gougeon M.-L.; Tiollais P.; Buendia M.A.

Generation of high affinity, fully human monoclonal antibodies specific to hepatitis B virus in a human/mouse radiation chimera: the trimera system
pp. 56-56(1)
Authors: Eren R.; Ilan E.; Lubin I.; Terkieltaub D.; Ben-Moshe O.; Arazi J.; Zauberman A.; Nussbaum O.; Berr S.; Galun E.; Shouval D.; Daudi N.; Reisner Y.; Magnius L.O.; Dagan S.

Alpha-interferon for chronic hepatitis B infection: increased efficacy of prolonged treatment
pp. 56-56(1)
Authors: Janssen H.L.A.; Honkoop P.; Gerken G.; Carreno V.; Heijtink R.A.; Schalm S.W.; European Concerted Action on Viral Hepatitis EUROHEP

Monocyte chemotactic protein-1 stimulates hepatic stellate cell chemotaxis
pp. 57-57(1)
Authors: Marra F.; Romanelli R.G.; Pastacaldi S.; Failli P.; Pinzani M.; Laffi G.; Gentilini P.

Effects of insulin and IGF-1 on human hepatic stellate cells (HHSC): role of PI 3- and map-kinase pathways
pp. 57-57(1)
Authors: Baroni G.S.; Ridolfi F.; Casini A.; Bendia E.; Jezequel A.M.; Pontiroli A.; Benedetti A.; Folli F.

Myofibroblasts overexpress osteonectin in hepatocellular carcinoma (HCC)
pp. 57-57(1)
Authors: Le Bail B.; Boussarie L.; Guirouilh J.; Carles J.; Bioulac-Sage P.; Balabaud C.; Rosenbaum J.

Hepatic stellate cell activation occurs in nonalcoholic steatohepatitis
pp. 57-57(1)
Authors: Pinto H.C.; Baptista A.; Camillo M.; Portela-Gomes G.; Carneiro de Moura M.

Expression of plasminogen activators and inhibitors in normal and fibrotic human liver
pp. 58-58(1)
Authors: Grappone C.; Pellegrini G.; Fibbi G.; Salzano R.; Casini A.; Del Rosso M.; Milani S.

Adhesion of human liver myofibroblasts to type I collagen specifically induces activation of gelatinase A
pp. 58-58(1)
Authors: Mavier P.; Preaux A.M.; d'Ortho M.P.; Mallat A.

Expression patterns of MMPs and TIMPs in liver cells in vitro: regulation by TNF-a and TGF-1
pp. 58-58(1)
Authors: Knittel T.; Mehde M.; Kobold D.; Saile B.; Ramadori G.

Functional and regulatory analysis of NF-B proteins during culture activation of hepatic stellate cells
pp. 58-58(1)
Authors: Elsharkawy A.; Hay R.; Arthur M.; Mann D.

Proinflammatory cytokines stimulate nitric oxide (NO) production and inducible nitric oxide synthase (iNOS) gene expression in rat cholangiocytes
pp. 59-59(1)
Authors: Granato A.; Calo L.; Spirli C.; LaRusso N.; Vianello D.; Duner E.; Okolicsanyi L.; Crepaldi G.; Strazzabosco M.

Distinct cytotoxic lymphocytes subsets suggest a role for the liver in immune homeostasis
pp. 59-59(1)
Authors: Doherty D.; Norris S.; Collins C.; McEntee G.; Traynor O.; Hegarty J.; O'Farrelly C.

Approaches to a murine model of AMA positive non-suppurative destructive cholangitis (NSDC)
pp. 59-59(1)
Authors: Bassendine M.; Palmer J.; Decruz D.; McCaughan G.; Strickland D.; Sedgewick J.; Yeaman S.; Burt A.; Jones D.

Immunotherapy of hepatocellular carcinoma (HCC) by engineering tumor cells to express B7-1 and/or IL-12
pp. 59-59(1)
Authors: Sun Y.; Qian C.; Peng D.; Prieto J.

Gene transfer into human hepatocellular carcinoma (HCC) cells in vitro and in vivo using recombinant adeno-associated virus (rAAV)
pp. 60-60(1)
Authors: Peng D.; Qian C.; Sun Y.; Prieto J.

Enhanced and stable integration of plasmid DNA into the genome of liver cells by non-viral gene transfer via adeno-associated virus inverted terminal repeats
pp. 60-60(1)
Authors: Steigerwald R.; Caselmann W.H.; Alt M.

Hepatocyte growth factor (HGF)-induced activation of the AP-1 complex : a comparison between normal and transformed rat hepatocytes
pp. 60-60(1)
Authors: Rahmani M.; Lardeux B.; Nadori F.; Bernuau D.

Regulation of HGF gene expression by TGF-1
pp. 60-60(1)
Authors: Harrison P.; Farzaneh F.

Pathways of T cell mediated cytotoxicity in hepatic allograft rejection
pp. 61-61(1)
Authors: Dollinger M.; Howie S.; Plevris J.; Hayes P.; Harrison D.

Systemic and hepatic venous concentrations of endothelin-1 and -3 in patients with hepatic encephalopathy. Relation to systemic and splanchnic hemodynamics
pp. 61-61(1)
Authors: Clemmesen J.; Gerbes A.; Gulberg V.; Larsen F.; Hansen B.; Ott P.

Oxidative stress contributes to the reduced tolerance of fatty livers to reperfusion injury
pp. 61-61(1)
Authors: Caraceni P.; Domenicali M.; Grattagliano I.; Morselli-Labate A.; Nardo B.; Simoncini M.; Trevisani F.; Altomare E.; Cavallari A.; Bernardi M.

Liver transplantation in patients with familial amyloidotic polyneuropathy (FAP) : study in a cohort of 29 patients and long-term results in 10 patients
pp. 61-61(1)
Authors: Adams D.; Samuel D.; Goulon-Goeau C.; Costa P.; Nakazato M.; Metral S.; Bismuth H.; Said G.

Prediction of hepatic encephalopathy in paracetamol (acetaminophen) overdose
pp. 62-62(1)
Authors: Schiodt F.; Bondesen S.; Tygstrup N.; Christensen E.

Gender influence on cold preservation-reoxygenation injury in rat liver
pp. 62-62(1)
Authors: Colantoni A.; De Maria N.; Caraceni P.; Bernardi M.; Keshavarzian A.; Van Thiel D.H.

Prognostic value of hepatocyte growth factor in haemophagocytic lymphohistiocytosis
pp. 62-62(1)
Authors: Hussain M.; Kallas M.; Mieli-Vergani G.; Vergani D.

Microgravity environment in a rotary cell culture system (RCCS) promotes cell aggregation and maintains differentiation and proliferation of primary porcine hepatocytes
pp. 62-62(1)
Authors: Dabos K.J.; Nelson L.J.; Plevris J.N.; Dollinger M.M.; Hewage C.; Sadler I.H.; Hayes P.C.

Assay to detect inhibitors of liver regeneration in acute liver failure
pp. 63-63(1)
Authors: Anderson C.; Thabrew M.I.; Hughes R.D.

Long term follow-up after liver transplantation for alveolar echinococcosis : a European retrospective analysis of 41 patients
pp. 63-63(1)
Authors: Koch S.; Bresson-Hadni S.; Heyd B.; Minello A.; Mantion G.; Vuitton D.; Miguet J.P.

Post-transplant lymphoproliferative disorders (PTLD) after liver transplantation (LT). Role of HCV infection
pp. 63-63(1)
Authors: Hezode C.; Duvoux C.; Germanidis G.; Roudot-Thoraval F.; Metreau J.; Bastie A.; Cherqui D.; Pawlotsky J.; Dhumeaux D.

Intraperitoneal perfusion of the supernatant of primary cultured hepatocytes prolongs survival of anhepatic rats
pp. 63-63(1)
Authors: Martel P.; Gigou M.; Castaing D.; Samuel D.; Bismuth H.; Feray C.

Long-term evolution of cardiovascular (CV) risk factors after liver transplantation (LT)
pp. 64-64(1)
Authors: Prieto M.; Garcia A.; Machancoses A.; Carrasco D.; Berenguer M.; Mir J.; Berenguer J.

Post liver transplant (LTx) acute HCV hepatitis and development of late complications
pp. 64-64(1)
Authors: Castells L.; Vargas V.; Margarit C.; Comas P.; Allende H.; Esteban R.; Guardia J.

Thrombopoietin(TPO) in cirrhosis and after orthotopic liver transplantation (OLT)
pp. 64-64(1)
Authors: Goulis J.; Chau T.; Jordan S.; Mehta A.; Rolles K.; Burroughs A.

Assessment of potential donors for living related liver transplantation
pp. 64-64(1)
Authors: Baker A.; Dhawan A.; Hadzic N.; Devlin J.; Curry E.; Southby E.; Mieli-Vergani G.; O'Grady J.; Rela M.; Heaton N.

Bone metabolism in chronic liver diseases before and after liver transplantation
pp. 65-65(1)
Authors: Trautwein C.; Possienke M.; Boker K.H.W.; Horn R.; Schlitt H.-J.; Pichlmayr R.; Brabant G.; Manns M.P.

Mixed cryoglobulinemia after liver transplantation (LT) for HCV cirrhosis. Prevalence and features
pp. 65-65(1)
Authors: Duvoux C.; Tran N.; Intrator L.; Germanidis G.; Pawlotsky J.; Cherqui D.; Dhumeaux D.

Liver transplantation in patients with Rendu-Osler-Weber disease
pp. 65-65(1)
Authors: Vasseur B.; Feray C.; Samuel D.; Reynes M.; Bismuth H.; Castaing D.

Natural history of HGV infection in HCV liver transplantation recipients
pp. 65-65(1)
Authors: T. Bizollon T.; S. Guichard S.; SiAhmed S.; Chevallier P.; Trepo C.

Ex-vivo liver perfusion: a successful technique of liver support
pp. 66-66(1)
Authors: Filipponi F.; Abouna G.M.; Boggi U.; Meacci L.; Burchielli S.; Barbieri U.; Bellentani S.; Fassati L.; Tiribelli C.; Costa G.

Alloreactivity of natural killer cells (NK) in allogeneic liver transplantation (LT)
pp. 66-66(1)
Authors: Oertel M.; Kohlhaw K.; Tannapfel A.; Lamesch P.; Schwarz R.; Schroder S.; Hauss J.; Mossner J.; Berr F.

Long term outcome in pediatric liver transplant recipients with Byler's disease
pp. 66-66(1)
Authors: Melter M.; Rodeck B.; Kardorff R.; Ehrich J.H.H.

Sodium salicylate (SA) protects hepatocytes but not endothelial cells during reperfusion after cold ischemia
pp. 66-66(1)
Authors: De Maria N.; Colantoni A.; Caraceni P.; Keshavarzian A.; Van Thiel D.H.

An endopeptidase as a sensitive marker of the quality of rat liver preservation
pp. 67-67(1)
Authors: Coradin K.; Nagaoka M.; Molina H.; Borges D.; Kouyomdjian M.

Prolonged seroprotection with a new HBIG against HBV reinfection after liver transplantation (OLT)
pp. 67-67(1)
Authors: Adler R.; Rowe M.; Shouval D.

Impact of HLA mismatching on paediatric liver transplantation (LT)
pp. 67-67(1)
Authors: Francavilla R.; Hadzic N.; Clare M.; Cheeseman P.; Underhill J.; Baker A.; Dhawan A.; Muiesan P.; Rela M.; Heaton N.; Mieli-Vergani G.; Donaldson P.

Soluble fas ligand levels during rejection after paediatric liver transplantation
pp. 67-67(1)
Authors: Hadzic N.; Hussain M.; Cheeseman P.; Francavilla R.; Mieli-Vergani G.; Vergani D.

(18F)fluorodeoxyglucose (FDG) positron emission tomography (PET) and neuropsychological study before and after liver transplantation (OLT)
pp. 68-68(1)
Authors: Burra P.; Pizzolato G.; Chierichetti F.; Tedeschi U.; D'Inca' R.; Fagiuoli S.; Floreani A.; Pittoni G.; Dam M.

Influence of fasting on hepatotoxicity and outcome in paracetamol overdose
pp. 68-68(1)
Authors: Bernal W.; Wicks C.; Wendon J.

Q-T interval prolongation in acute liver failure: relationship with etiology and outcome of disease
pp. 68-68(1)
Authors: Calandra S.; Wendon J.

Maintenance of high energy phosphate levels in hypothermic reperfusion of stored pig livers: a ³¹P MR spectroscopy (MRS) study
pp. 68-68(1)
Authors: Taylor-Robinson S.; Changani K.; Bell J.; Fuller B.; Davidson B.

Prediction of prognosis after transplantation in primary sclerosing cholangitis using a cox model
pp. 69-69(1)
Authors: Neuberger J.; Gunson B.; Christensen E.

Mixed cryoglobulinemia after liver transplantation for HCV-positive liver cirrhosis
pp. 69-69(1)
Authors: Puliti S.; Feray C.; Gigou M.; Giannelli F.; Marrocchi E.; Filipponi F.; Samuel D.; Gentilini P.; Zignego A.

Immunogenetic factors, HCV genotype and HCV recurrence after liver transplantation
pp. 69-69(1)
Authors: Belli L.; Zavaglia C.; Alberti A.; Silini E.; Poli F.; De Carlis L.; Rondinara G.; Scalamogna M.; Forti D.; Ideo G.

Posttransplant lymphoproliferative disorder (PTLD) in liver recipients
pp. 69-69(1)
Authors: Ben-Ari Z.; Amlot P.; Lachmanan S.; Tur-Kaspa R.; Rolles K.; Burroughs A.K.

Effect of cisapride upon jejunal bacterial flora and Bacterial Translocation (BT) in ascitic cirrhotic rats
pp. 70-70(1)
Authors: Bartoli R.; Pardo A.; Planas R.; Vinado B.; Cabre E.; Rodriguez-Iglesias M.P.; Ausina V.; Gassull M.

L-Ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action
pp. 70-70(1)
Authors: Butterworth R.F.; Rose C.; Quack G.; Kircheis G.

Patch-clamp evidence for an alteration of large-conductance Ca²⁺-activated K⁺ (KCa) channels in arterial smooth muscle cells (SMC) from rats with cirrhosis
pp. 70-70(1)
Authors: Moreau R.; Paulais M.; Marvao P.; Tazi K.; Lebrec D.; Teulon J.

The treatment of the type 1 hepatorenal syndrome (HRS) with the combined administration of midodrine and octreotide
pp. 70-70(1)
Authors: Angeli P.; Volpin R.; Gerunda G.; Craighero R.; Con P.; Caregaro L.; Merkel C.; Sticca A.; Maffei-Faccioli A.; Gatta A.

Hepatocytes contribute to the increased hepatic production of cysteinyl leukotrienes in rats with cirrhosis
pp. 71-71(1)
Authors: Titos E.; Claria J.; Jimenez W.; Bosch M.; Arroyo V.; Rivera F.; Rodes J.

Renal sodium handling in pre-ascitic cirrhosis evaluated with creatinine and lithium clearance determination during cimetidine administration
pp. 71-71(1)
Authors: Sansoe G.; Ferrari A.; Castellana C.; Villa E.; Manenti F.

Prefrontal dysfunction in cirrhotic patients without overt hepatic encephalopathy detected by the stroop test
pp. 71-71(1)
Authors: Amodio P.; Quarello A.; Del Piccolo F.; Bergamelli C.; Marchetti P.; Merkel C.; Caregaro L.; Perini G.; Gatta A.

Tolerance to nitroglycerin in rats with experimental liver cirrhosis: an in vitro study on aortic rings
pp. 71-71(1)
Authors: Nagy I.; Szilvassy Z.

Activation of ito-cells in culture is preceded by an increase in the sensitivity to endothelin-1 but not to purinergic or 1-adrenergic agonists
pp. 72-72(1)
Authors: Reinehr R.; Kubitz R.; Peters-Regehr T.; Bode J.; Haussinger D.

Relationship between autonomic neuropathy and hyperdynamic circulation in cirrhosis
pp. 72-72(1)
Authors: Trevisani F.; Sica G.; Mainqua P.; Caraceni P.; Domenicali M.; De Notariis S.; Angelini G.R.; Bernardi M.

Reduction of vascular compliance by propranolol influences the portal pressure response to pharmacological therapy
pp. 72-72(1)
Authors: Andreu V.; Bandi J.; Escorsell A.; Castaneda B.; Perello A.; Debernardi-Venon W.; Moitinho E.; Garcia-Pagan J.; Bosch J.; Rodes J.

Splanchnic impedance indices in portal hypertension
pp. 72-72(1)
Authors: Bolognesi M.; Sacerdoti D.; Bombonato G.; Favero A.; Gatta A.

Altered ''peripheral-type'' benzodiazepine receptor (PTBR) gene expression in brain and testis following end-to-side portacaval anastomosis
pp. 73-73(1)
Authors: Butterworth R.F.; Desjardins P.; Bandeira P.; Hazell A.S.

The activity of cyclic guanosine monphosphate specific phosphodiesterase (cGMP-PDE) in the renal tissue and the blunted renal responsiveness to endogenous natriuretic peptides (ENP) in cirrhotic rats with ascites
pp. 73-73(1)
Authors: Veggian R.; Angeli P.; Fasolato S.; Sticca A.; Craighero R.; Dalla Libera V.; Garbisa S.; Gatta A.

Effect of insulin-like growth factor-I (IGF-I) on the jejunal transport of amino acids in cirrhotic rats
pp. 73-73(1)
Authors: Pascual M.; Castilla-Cortazar I.; Urdaneta E.; Perez R.; Quiroga J.; Prieto J.; Santidrian S.

Jejunal microvilli atrophy and reduced sugar transport in rats with advanced liver cirrhosis: improvement by insulin-like growth factor (IGF-I)
pp. 73-73(1)
Authors: Castilla-Cortazar I.; Pascual M.; Urdaneta E.; Garcia M.; Trigueros J.; Quiroga J.; Prieto J.; Santidrian S.

Rat liver myofibroblasts and activated hepatic stellate cells: two different cell populations of the fibroblast lineage involved in hepatic tissue repair
pp. 74-74(1)
Authors: Knittel T.; Kobold D.; Saile B.; Mehde M.; Ramadori G.

RCT of variceal ligation (VL) vs propranolol-iso sorbide (PI) for variceal rebleeding with target pressure reduction: methodological problems
pp. 74-74(1)
Authors: Goulis J.; Patch D.; Greenslade L.; Gerunda G.; Merkel C.; Burroughs A.K.

TNF- production induced by LPS endotoxin is augmented in rats with portal hypertension
pp. 74-74(1)
Authors: Perez del Pulgar S.; Pizcueta P.; Engel P.; Bosch J.; Rodes J.

Somatostatin is less effective decreasing portal pressure during acute variceal bleeding than in stable conditions
pp. 74-74(1)
Authors: Moltinho E.; Escorsell A.; Bandi J.; Garcia-Pagan J.; Castaneda B.; Andreu V.; Bosch J.; Rodes J.

Tips for severe hepatorenal syndrome in non-transplant cirrhotics: a new option?!
pp. 75-75(1)
Authors: Brensing K.; Textor J.; Perz J.; Schiedermaier P.; Raab P.; Strunk H.; Klehr H.; Kramer H.; Spengler U.; Schild H.; Sauerbruch T.

Silymarin increases retinyl ester concentration in rats with secondary biliary cirrhosis
pp. 75-75(1)
Authors: Boigk G.; Heinrich F.; Biesalski H.K.; Herbst H.; Jia J.D.; Riecken E.O.; Schuppan D.

Early portosystemic encephalopathy is related to hepatic arterial flow reserve in patients with cirrhosis
pp. 75-75(1)
Authors: Zipprich A.; Lotterer E.; Steudel N.; Hoppe M.; Behrmann C.; Kleber G.; Fleig W.E.

Sympathoinhibitory effects of total paracentesis (TP) in cirrhosis: microneurographic studies
pp. 75-75(1)
Authors: Pozzi M.; Pecci V.; Turri C.; Vailati S.; Roffi L.; Massironi S.; Boari G.; Carugo S.; Giannattasio C.; Grassi G.; Mancia G.

Sinusoidal but not prehepatic portal pressure is associated with decreased hepatic no synthase (NOS) activity
pp. 76-76(1)
Authors: Fluck M.; Van de Casteele M.; Klossner W.; Sagesser H.; Zimmermann H.; Reichen J.

Organ specific expression of endothelin 1 in biliary cirrhosis in the rat
pp. 76-76(1)
Authors: De Gottardi A.; Shaw S.; Boden J.; Hosli M.; Reichen J.

Effect of chronic treatment with nadolol plus isosorbide-5-mononitrate on liver blood flow and liver metabolic activity in cirrhosis
pp. 76-76(1)
Authors: Merkel C.; Sacerdoti D.; Bolognesi M.; Buonamico P.; Amodio P.; Angeli P.; Gatta A.

Lipoic acid prevents development of the hyperdynamic circulation in experimental cirrhosis
pp. 76-76(1)
Authors: Marley R.; Fernando B.; Holt S.; Harry D.; Anand R.; Moore K.

Thrombopoietin-deficiency, DIC, thrombocyte consumption, and thrombocytopenia in cirrhosis
pp. 77-77(1)
Authors: Peck-Radosavljevic M.; Wichlas M.; Zacherl J.; Stiegler G.; Stohlawetz P.; Panzer S.; Steininger R.; Ferenci P.; Pidlich J.; Gangl A.

Prospective study of the correlation between the development of liver fibrosis and hemodynamic changes in patients with HCV infection
pp. 77-77(1)
Authors: Elman A.; Degott C.; Denie C.; Valla D.; Gadano A.; Yang S.; Vachiery F.; Sogni P.; Moreau R.; Erlinger S.; Lebrec D.

Cholyl lysylfluorescein (CLF) plasma clearance in patients with liver diseases: a new dynamic liver function test?
pp. 77-77(1)
Authors: Milkiewicz P.; Saksena S.; Cardenas T.; Mills C.; Elias E.

A randomized trial comparing endoscopic ligation with nadolol plus isosorbide-5-mononitrate for the prevention of variceal rebleeding, preliminary results
pp. 77-77(1)
Authors: Gallego A.; Villanueva C.; Ortiz J.; Minana J.; Soriano G.; Ricart E.; Torras X.; Sainz S.; Kolle L.; Guarner C.; Balanzo J.

Emergency tips for refractory variceal bleeding
pp. 78-78(1)
Authors: Bizollon T.; Dumortier J.; Jouisse C.; Ahmed S.S.; Rode A.; Valette P.; Paliard P.; Trepo C.

Cohort effect of HCV infection in a cirrhotic population: a 25 years examination
pp. 78-78(1)
Authors: Croce L.S.; Stanta G.; Bonin S.; Tisminetzky S.G.; Baralle F.E.; Tiribelli C.

N-Acetylcysteine (NAC) protects hepatic mitochondria from oxidative alterations in bile duct ligated (BDL) rats
pp. 78-78(1)
Authors: Vendemiale G.; Grattagliano I.; Didonna D.; Altomare E.

Effect of transjugular intrahepatic portosystemic shunt (TIPS) on renal function and vasoactive systems in hepatorenal syndrome (SHR)
pp. 78-78(1)
Authors: Guevara M.; Gines P.; Sort P.; Bandi J.; Jimenez W.; Gilabert R.; Bosch J.; Arroyo V.; Rodes J.

Continuing thrombocytopenia post tips: inadequate bone marrow production, not platelet consumption
pp. 79-79(1)
Authors: Wichlas M.; Pidlich J.; Zacherl J.; Panzer S.; Ferenci P.; Gangl A.; Peck-Radosavljevic M.

Lack of prognosic usefulness of hepatic pressures and hemodynamic values in patients with alcoholic cirrhosis: a prospective study
pp. 79-79(1)
Authors: Deltenre P.; Ruffat P.; Hillaire S.; Vachiery F.; Elman A.; Moreau R.; Valla D.; Erlinger S.; Lebrec D.

Cardiac and renal response to posture in cirrhotics with and without essential hypertension
pp. 79-79(1)
Authors: Gentilini P.; Barletta G.; Romanelli R.G.; Laffi G.; La Villa G.

Albumin improves response to diuretics in decompensated cirrhotic patients
pp. 79-79(1)
Authors: Gentilini P.; Raggi V.C.; Romanelli R.G.; La Villa G.; Laffi G.

Long term course and prognostic factors in HCV-related compensated cirrhosis
pp. 80-80(1)
Authors: Farmachidi J.; Rufat P.; Vilgrain V.; Njapoum C.; Valla D.; Marcellin P.; Erlinger S.; Degos F.

Norfloxacin versus ofloxacin in the prophylaxis of infection in cirrhotic patients with gastrointestinal (GI) hemorrhage
pp. 80-80(1)
Author: Spanish Group for the Study of Bacterial Infections in Cirrhosis

Genetic instability and mismatch repair genes in liver biopsies from patients with advanced liver cirrhosis and from patients with hepatocellular carcinoma developed in previous cirrhosis
pp. 81-81(1)
Authors: Garcia-Foncillas J.; Riezu J.I.; Herrero J.I.; Civeira M.P.; Prieto J.

Constitutive and lipopolysaccharide regulated gene expression of the antioxidant heme oxygenase-1 in kupffer cells of rat liver
pp. 81-81(1)
Authors: Immenschuh S.; Tan M.; Kietzmann T.; Ramadori G.

Matrix protein expression in sinusoidal endothelial cells: modulation by TGF-1
pp. 81-81(1)
Authors: Neubauer K.; Kruger M.; Quondamattteo F.; Knittel T.; Ramadori G.

Mast cell protease and stem cell factor expression in rat liver fibrosis
pp. 81-81(1)
Authors: Gaca M.; Arthur M.; Benyon R.

Differential activity of iron regulatory protein (IRP)-2 in liver and hepatoma cell lines
pp. 82-82(1)
Authors: Recalcati S.; Conte D.; Cairo G.

Mitogens generate positive and negative signals for human hepatic stellate cell proliferation
pp. 82-82(1)
Authors: Mallat A.; Gallois C.; Jiangchuang T.; Habib A.; Maclouf J.; Mavier P.; Preaux A.-M.; Lotersztajn S.

H₂O₂ and 4-hydroxy-2,3-alkenals affect basal- and PDGF-dependent proliferation in human hepatic stellate cells (HSC)
pp. 82-82(1)
Authors: Robino G.; Caligiuri A.; De Franco R.; Sali C.; Dianzani M.U.; Gentilini P.; Parola M.; Pinzani M.

Endothelin induced activation of hepatic stellate cells is via JNK and p38 map kinases
pp. 82-82(1)
Authors: Dack C.L.; Day C.P.; Burt A.D.; Reeves H.L.

Non-transferrin-bound iron (NTBI) transport and transferrin receptors are differently regulated by no generators in HepG2 cells
pp. 83-83(1)
Authors: Barisani D.; Cairo a.; Conte a.

Potential role of NF-kB in the negative regulation of human hepatic stellate cell proliferation
pp. 83-83(1)
Authors: Gallois C.; Habib A.; Jiangchuang T.; Maclouf J.; Mallat A.; Lotersztajn S.

Modulation of cellular fibronectin (cFN) in mononuclear phagocytes (MP) from CCL₄-treated rats. in vitro and in vivo study
pp. 83-83(1)
Authors: Armbrust T.; Kreiszig M.; Herbst H.; Ramadori G.

Generation of reactive oxygen species and NO^* in the early phase of fibrosis: effect of interferon-
pp. 83-83(1)
Authors: Svegliati-Baroni G.; de Jager-Krikken A.; Saccomanno S.; Jansen P.L.M.; Jezequel A.M.; Moshage H.

The C-terminal peptide of antitrypsin (AAT) increases LDL binding in HepG2 cells
pp. 84-84(1)
Authors: Janciauskiene S.; Lindgren S.

Cellular localization and regulation of cytochrome P450-1B1 in different liver cell populations
pp. 84-84(1)
Authors: Piscaglia F.; Knittel T.; Kobold D.; Ramadori G.

Modulation of proliferation and apoptosis in hepatic stellate cells by TGF- and/ or TNF- is dependent on the status of activation
pp. 84-84(1)
Authors: Saile B.; Matthes N.; Knittel T.; Ramadori G.

Survival of patients with hepatocellular carcinoma (HCC) is determined by type of liver estrogen receptors
pp. 84-84(1)
Authors: Villa E.; Fantoni E.; Moles A.; Camellini L.; Buttafoco P.; Grottola A.; Ferretti I.; Manenti F.

Regulation of hepatocyte growth factor gene expression by N-acetylcysteine
pp. 85-85(1)
Authors: Harrison P.; Farzaneh F.

Differential expression of tenascin isoforms in acute and chronic human liver injury
pp. 85-85(1)
Authors: Pellegrini G.; Grappone C.; Zardi L.; Borsi L.; Schuppan D.; Herbst H.; Casini A.; Salzano R.; Milani S.

The possible implication of 5'-nucleotidase as an insulin-sensitive enzyme and modulator of adenosine concentration in rat liver
pp. 85-85(1)
Authors: Kocic R.; Kocic G.; Vlahovic P.; Jevtovic T.; Pavlovic D.

Enhanced expression of 5-lipoxygenase (5-LO) in biliary cirrhosis in the rat
pp. 85-85(1)
Authors: Albrecht C.; Luthi M.; Reichen J.

Differentially expressed genes in cirrhosis: betaine - homocysteine methyltransferase (BHMT) is reduced in bile duct ligated rat liver
pp. 86-86(1)
Authors: Forestier M.; Banninger R.; Reichen J.; Solioz M.

Changes in hepatic matrix degradation in prefibrotic and fibrotic haemochromatosis
pp. 86-86(1)
Authors: George D.; Ramm G.; Powell L.; Crawford D.

Analysis of gene expression during hepatocarcinogenesis: use of mRNA differential display
pp. 86-86(1)
Authors: Cimino L.; Ammendola R.; De Felice C.; Budillon G.; Cimino F.

The role of metalloproteinases in CCl4 induced fibrosis. Influence of zinc administration
pp. 86-86(1)
Authors: Gimenez A.; Gasso M.; Roman J.; Caballeria J.; Deulofeu R.; Rubio M.; Pares A.; Ballesta A.M.; Rodes J.

Large scale screening of HBV-DNA integration sites into human liver tumor DNA: evidence for serca 1 HBV mediated cisactivation
pp. 87-87(1)
Authors: Saigo K.; Chami M.; Poussin K.; Clepet C.; Gyapay G.; Caudron B.; Urashima T.; Kew M.; Isono K.; Wessenbach J.; Brechot C.; Paterlini P.

Molecular bases of X induced cell cycle arrest and apoptosis
pp. 87-87(1)
Authors: Sirma H.; Giannini C.; Kremsdorf D.; Brechot C.

Con a induced liver injury: a new model to study hepatocyte proliferation
pp. 87-87(1)
Authors: Trautwein C.; Rakemann T.; Malek N.; Plumpe J.; Tiegs G.; Manns M.

Expression of a truncated -catenin mRNA in human liver cancer cells, a possible marker of neoplasia
pp. 87-87(1)
Authors: Cervello M.; Giannitrapani L.; Gambino R.; Notarbartolo M.; Miceli M.D.; Farruggio R.; Virruso L.; Castagnetta L.; Montalto G.

Hepatocyte growth factor (HGF) stimulates the proliferation of HepG2 cells: role of the AP-1 transcrition complex
pp. 88-88(1)
Authors: Malekkiani N.; Bringuier A.; Bernuau D.

Polymorphic genomic fingerprinting of synchronous hepatocellular cancers identified by arbitrarily primed-polymerase chain reaction (AP-PCR)
pp. 88-88(1)
Authors: Sirivatanauksorn Y.; Sirivatanauksorn V.; Bhattacharya S.; Savage K.; Rees J.; Dhillon A.; Lemoine N.; Williamson R.; Davidson B.

Fas and Fas-ligand expression in hepatocellular carcinoma and adjacent liver parenchyma: does cancer induce suicide in the peritumoral cells?
pp. 88-88(1)
Authors: Roskams T.; Van Damme B.; Desmet V.

Mitochondrial benzodiazepine receptor system in hepatocellular carcinoma: a possible mechanism of resistance to death during cell proliferation
pp. 88-88(1)
Authors: Venturini I.; Zeneroli M.L.; Corsi L.; Pellicci R.; Ardizzone G.; Arrigo A.; Farina F.; Ferrarese C.; Pecora N.; Frigo M.; Avallone R.; Baraldi M.

Prevalence and predictive factors of large cell dysplasia (LCD) in chronic liver diseases
pp. 89-89(1)
Authors: Arotcarena R.; Guettier C.; Ganne-Carrie N.; Christidis C.; Trinchet J.; Beaugrand M.

Clinical validation of the influence of P-glycoprotein on ^99mTc-MIBI uptake in ^99mTc-MIBI spect in hepatocellular carcinoma
pp. 89-89(1)
Authors: Kim Y.S.; Cho S.W.; Kim I.H.; Wang H.I.; Jin Y.M.; Park C.H.

Detection of HCC in liver cirrhosis: comparison of nonenhanced, SPIO-enhanced MRI or lipiodol-CT
pp. 89-89(1)
Authors: Caseiro Alves F.; Belo Soares P.; Cipriano M.A.; Carvalho A.; Santos R.; Perdigoto R.

Suppression of P21^WAF1/CIP1 inhibits P53 mediated apoptosis in hepatocellular carcinoma cell line
pp. 89-89(1)
Authors: Yang F.; Wang W.

Expression pattern of collagen XVIII in HCC
pp. 90-90(1)
Authors: Cramer T.; Bauer M.; Herbst H.; Riecken E.O.; Schuppan D.

Expression of acidic and basic fibroblast growth factor and hepatocyte growth factor in regenerating human liver after submassive necrosis
pp. 90-90(1)
Authors: Roskams T.; Van Damme B.; Desmet V.

Ability of neoplastic liver tissue to take up cytostatic bile acid derivatives
pp. 90-90(1)
Authors: Monte M.J.; Dominguez S.M.; Macias R.I.R.; Dominguez M.F.; Serrano M.A.; Marin J.J.G.

CYP2E1 inducers modulate valproic acid toxicity and induces 4-ene-valproic acid apoptosis in Hep G2 cells
pp. 90-90(1)
Authors: Neuman M.; Shear N.; Malkiewicz I.; Abbott F.

Iatrogenic spreading of liver derived cells by liver resection and needle biopsy in patients with primary liver cancer
pp. 91-91(1)
Authors: Louha M.; Nicolet J.; Sabile M.; Zylberberg H.; Vons C.; Vona G.; Capron F.; Poussin K.; Pol S.; Nalpas S.B.; Franco D.; Brechot C.; Paterlini P.

BCL-2 rearrangement in mixed cryoglobulinemia and HCV-positive liver disease patients
pp. 91-91(1)
Authors: Zignego A.L.; Giannelli F.; Giannini C.; Ferri C.; Marrocchi M.; Mazzocca A.; Laffi G.; Gentilini P.

The influence of liver atrophy and hypertrophy on the growth of hepatocellular carcinoma in the ACI rat
pp. 91-91(1)
Authors: Abou-Shady M.; Friess H.; Zimmermann A.; Baer H.U.

Flat bile acids in rat bile during liver carcinogenesis
pp. 91-91(1)
Authors: Marin J.J.G.; El-Mir M.Y.; Palomero M.F.; Badia M.D.; Monte M.J.; Dominguez M.; Torano A.

King's college hospital experience of OLT for HCC
pp. 92-92(1)
Authors: McCall J.; Rela M.; Kallife M.; Muiesan P.; Gibbs P.; Karani J.; Portmann B.; O'Grady J.; Heaton N.

Granulocyte-colony stimulating factor administration accelerates hepatocyte proliferation in carbon tetrachloride induced rat liver injury
pp. 92-92(1)
Authors: Theocharis S.; Margeli A.; Kouraklis G.; Mykoniatis M.; Kittas C.

Tissue characterization of small hepatic tumors. Quantitative doppler spectral analysis vs. power doppler flow imaging
pp. 92-92(1)
Authors: Gaiani S.; Casali A.M.; Serra C.; Piscaglia F.; Venturoli N.; Gramantieri L.; Valgimigli M.; Bolondi L.

Histological variables predictive of hepatocellular carcinoma (HCC) in patients with genetic hemochromatosis (GH)
pp. 92-92(1)
Authors: Fracanzani A.; Roncalli M.; Borzio M.; Derenzini M.; Trere M.; Del Vitto M.; Molteni V.; Fiorelli G.; Fargion S.

Iron as risk factor for hepatocellular carcinoma
pp. 93-93(1)
Authors: Fargion S.; Mattioli M.; Sampietro M.; Rossi G.; Saltarin L.; Lupica L.; Fracanzani A.; David E.; Fassati L.; Fiorelli G.

In vivo and in vitro effect of INF- 2b on the activity of adenosine metabolizing enzymes in rat liver
pp. 93-93(1)
Authors: Kocic G.; Kocic R.; Pavlovic D.; Kocic B.; Cvetkovic T.; Jevtovic T.

Enzyme expressions in hepatocellular tumors, thymidine phosphorylase and thymidylate synthase, predict tumor response to 5-fluorouracil
pp. 93-93(1)
Authors: Abonyi M.; Galffy G.

In vitro infection of hepatitis B virus in microcarrier attached immortalized human hepatocytes cultured in molecularporous membrane bags: a model for long-term HBV infection
pp. 94-94(1)
Authors: Gong Z.J.; De Meyer S.; Verslype C.; Roskams T.; van Pelt J.F.; Soumillion A.; Crabbe T.; Yap S.H.

High prevalence of ''occult'' HBV infection and evidences of suppressed HBV gene expression in patients with HCV-related chronic hepatitis
pp. 94-94(1)
Authors: Cacciola I.; Pollicino T.; Squadrito G.; Cerenzia G.; Longo G.; Raimondo G.

The influence of the HLA class II allele DQB1*0301 on HCV specific T helper cell responses
pp. 94-94(1)
Authors: Cramp M.E.; Rossol S.; Carucci P.; Williams R.; Naoumov N.V.; Donaldson P.T.

Predicted patterns of emergence of vaccine resistant strains of hepatitis B virus
pp. 94-94(1)
Authors: Wilson J.; Nokes D.; Carman W.

HCV NS5A protein: subcellular localization by fluorescence and electron microscopy
pp. 95-95(1)
Authors: Bono F.; Candusso M.E.; Silini E.M.

MHC Class II and the outcome of HCV infection
pp. 95-95(1)
Authors: Thursz M.R.; Yallop R.; Mantafounis D.; Trepo C.; Thomas H.C.

Differential effect of IFN alpha-2b and ribavirin on the HCV-RNA level in primary cultures of human hepatocytes derived from chronic HCV carriers and of human hepatocytes infected in vitro
pp. 95-95(1)
Authors: Clarysse C.; Nevens F.; Pirenne J.; Aerts R.; Soumillion A.; Roberts N.; Yap S.H.

Functional implications of the X interaction with the proteasome
pp. 95-95(1)
Authors: Sirma H.; Weil R.; Strohwasser R.; Kloetzel K.; Israel A.; Kremsdorf D.; Brechot C.

Hepatitis B virus has a recent new world evolutionary origin
pp. 96-96(1)
Authors: Bollyky P.; Rambaut A.; Grassley N.; Carman W.; Holmes E.

Two motifs involved in controlling transcription of the HBV S promoter
pp. 96-96(1)
Authors: Trautwein C.; Bock C.T.; Kubicka S.; Manns M.P.

Human cytotoxic T cell recognition of hepatitis C virus (HCV) core protein
pp. 96-96(1)
Authors: Jackson M.; Bassendine M.F.; Toms G.L.; Diamond A.G.

Neutralizing antibodies against HCV: liver transplant as an experimental model
pp. 96-96(1)
Authors: Villa E.; Buttafoco P.; Grottola A.; Scarcelli A.; Giannini F.; Manenti F.

Type I interferon gene expression in chronic hepatitis C virus infection
pp. 97-97(1)
Authors: Castelruiz Y.; Larrea E.; Alberdi A.; Bova P.; Civeira M.P.; Prieto J.

Liver HCV RNA is correlated to Fas mRNA and to apoptosis in liver transplanted patients infected by hepatitis C
pp. 97-97(1)
Authors: Feray C.; Brenot C.; Di Martino V.; Samuel D.; Saurini F.; Petit M.; Reynes M.; Bismuth H.

Epitope mapping of the 'A' determinant region of HBV variants reveal marked changes: implications for design of assays for diagnosis of HBV infection
pp. 97-97(1)
Authors: Tonekaboni S.; Waters J.; Jeffers S.; Karayiannis P.; Thomas H.C.

Phylogenetic analysis of hepatitis G virus (HGV) 5'-non coding region and development of a rapid PCR-based typing assay
pp. 97-97(1)
Authors: Silini E.; Schluter V.; Asti M.; Bissolati M.; Lisa A.; Sonzogni L.; Mondelli M.U.

Relative quantification and mapping of hepatitis C virus by ''in situ'' hybridization and digital image analysis
pp. 98-98(1)
Authors: Rodriguez-Inigo E.; Gosalvez J.; Bartolome J.; Ramiro-Diaz J.; Tomas J.; Carreno V.

CD5 B lymphocytes are increased in hepatitis C virus infection
pp. 98-98(1)
Authors: Curry M.P.; Golden-Mason L.; Hannigan E.; Parfrey N.A.; Hegarty J.E.; Farrelly C.O.

Liver iron distribution, histological activity and mutations in the hemochromatosis gene (HFE) in chronic hepatitis C
pp. 98-98(1)
Authors: Sampietro M.; Boldorini R.; Corbetta N.; Amato M.; Casatta A.; Lupica L.; Nunziata R.; Mattioli M.; Del Vitto M.; Molteni V.; Fracanzani A.L.; Fargion S.; Fiorelli G.

Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with severity of liver disease
pp. 98-98(1)
Authors: Zylberberg H.; Rimaniol A.; Pol S.; De Groote D.; Berthelot P.; Bach J.-F.; Brechot C.; Zavala F.

Association of high viral load with suppressed costimulatory effects of IL-12 on HBV-induced immune response
pp. 99-99(1)
Authors: Schlaak J.F.; Tully G.; Lohr H.F.; Gerken G.; Meyer zum Buschenfelde K.-H.

HCV core protein and the expression of the alpha-foetoprotein gene
pp. 99-99(1)
Authors: Verslype C.; Wu C.-G.; van Pelt J.F.; Yap S.H.

Enhanced intrahepatic MxA expression in-fulminant hepatitis
pp. 99-99(1)
Authors: Leifeld L.; Ramakers J.; Haller O.; Trautwein C.; Dumoulin F.; Muller A.; Sauerbruch T.; Spengler U.

Hepatitis B virus X protein transactivates the hepatic inducible nitric oxide synthase promoter
pp. 99-99(1)
Authors: Bartolome J.; Amaro M.J.; Carreno V.

Genetic diversity and tissue compartmentalization of hepatitis C virus (HCV) genome in blood mononuclear cells, liver and serum from chronic hepatitis C patients
pp. 100-100(1)
Authors: Navas S.; Martin J.; Quiroga J.A.; Castillo I.; Carreno V.

Titration of intrahepatic (-) HCV RNA by strand-specific RT-PCR in chronic hepatitis C: morphological and clinical correlations
pp. 100-100(1)
Authors: Negro F.; Krawczynski K.; Quadri R.; Mondelli M.; Rubbia-Brandt L.; Baud M.; Zarski J.-P.; Hadengue A.

Interaction of iron metabolism with cellular immune function in HCV infection
pp. 100-100(1)
Authors: Umlauft F.; Urbanek M.; Herold M.; Vogel W.; Weiss G.

Viral and host factors contribute to fulminant hepatitis following infection with the hbeag negative variant
pp. 100-100(1)
Authors: Karayiannis P.; Guo Y.; Hadziyannis S.; Alexopoulou A.; Thursz M.; Thomas H.C.

Correlation of transforming growth factor 1, apoptosis and proliferation in chronic hepatitis C
pp. 101-101(1)
Authors: Schaff Z.; Jarmay K.; Szepesi A.; Szalay F.; Patonai A.; Nemes B.; Lotz G.; Lonovics J.

Inhibitory effect of 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) on hepatitis B virus replication in vitro
pp. 101-101(1)
Authors: Gong Z.J.; De Meyer S.; Verslype C.; Coopmans T.; Soumillion A.; Neyts J.; De Clerq E.; Yap S.H.

Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides in vitro
pp. 101-101(1)
Authors: Yao Z.Q.; Huang A.Q.; Shi D.R.; Zhou Y.X.; Yap S.H.

Anti conformational CYP2D6 antibody levels correlate with histologically assessed liver damage in patients with LKM1 positive chronic hepatitis C
pp. 101-101(1)
Authors: Ma Y.; Muratori L.; Lenzi M.; Williams R.; Bianchi F.B.; Vergani D.

Transmission of hepatitis C virus infection to tree shrews
pp. 102-102(1)
Authors: Xie Z.C.; Riezu-Boj J.I.; Lasarte J.J.; Guillen J.; Su J.H.; Civeira M.P.; Prieto J.

Natural killer (NK) cells in patients with chronic hepatitis C (CHC)
pp. 102-102(1)
Authors: Lirussi F.; Sanchez B.; Pellizzari L.; Guglietta A.

Genetic polymorphisms and seric expression of ICAM-1 in HCV infected patients
pp. 102-102(1)
Authors: Gallego A.; Perez C.; Torras X.; Dedeu J.; Gomez C.; Corral E.; Crusius J.B.A.; Enriquez J.

The influences of immunosuppressive agents on HBV replication in vitro
pp. 102-102(1)
Authors: Gong Z.J.; De Meyer S.; Wu C.-G.; Clarysse C.; Crabbe T.; Neyts J.; De Clerq E.; Yap S.H.

Association of infection with a specific hepatitis G virus strain with fulminant hepatitis
pp. 103-103(1)
Authors: Sheng L.; Soumillion A.; Beckers N.; Wu C.-G.; Verslype C.; Nevens F.; Pirenne J.; Aerts R.; Kosala H.; Fevery J.; H. Yap S.

Differential anti-hepatitis B virus activity in vitro of three potent of inosine monophosphate dehydrogenase inhibitors: mycophenolic acid (MPA), 5-ethynyl-1--d-ribofuranosyli-midazole-4-carboxamide (EICAR) and ribavirin
pp. 103-103(1)
Authors: Gong Z.J.; De Meyer S.; Clarysse C.; van Pelt J.F.; Coopmans T.; Neyts J.; De Clerq E.; Yap S.H.

Modulation of IFN- signalling by NSAIDs: therapeutic implications in HCV patients
pp. 103-103(1)
Authors: Giambartolomei S.; Artini M.; Almerighi C.; Levrero M.; Balsano C.

HCV related mixed cryoglobulinemia is associate with high liver HCV load
pp. 103-103(1)
Authors: Lari F.; Ballardini G.; Lenzi M.; Ghetti S.; Grassi A.; Propato N.; Descovich C.; Zauli D.; Bianchi F.

Effects of amantadine and amantadine/interferon2a on peripheral blood mononuclear cells (PBMC) from chronic hepatitis C patients and healthy donors
pp. 104-104(1)
Authors: Martin J.; Navas S.; Fernandez M.; Rico M.; Pardo M.; Quiroga J.A.; Carreno V.

Analysis of the HBV precore and ORF-X sequences in anti-HBe positive patients with and without normal ALT levels
pp. 104-104(1)
Authors: Cabrerizo M.; Bartolome J.; Inigo E.R.; Lopez-Alcorocho J.M.; Cotonat T.; Carreno V.

HBV DNA inhibits production of TGF1 which in turn inhibits HBsAg production
pp. 104-104(1)
Authors: Hobbins B.L.; Greer S.; Smith H.M.; Alexander G.J.M.

Comparison between HCVRNA AND E1/E2 antibodies in patients on IFN treatment
pp. 104-104(1)
Authors: Mangia A.; Maertens G.; Cascavilla I.; Santantonio T.; Conoscitore P.; Andriulli A.

Amantadine in HCV chronic infection: A 6 months follow-up study
pp. 105-105(1)
Authors: Mangia A.; Facciorusso D.; Lezzi G.; Villani M.; Gentile R.; Rizzetto M.; Andriulli A.

The influence of viral load, ALT and genotypes on the viral genetic heterogeneity (quasispecies) in Turkish patients with chronic hepatitis C virus(HCV) infection
pp. 105-105(1)
Authors: Bozdayi A.M.; Uzunalimoglu O.; Asian N.; Bozkaya H.; Turkylilmaz A.R.; Kayhan B.; Sahin T.; Alper A.; Cetinkaya H.; Karayalcin S.; Yurdaydin C.

Comparative study of solution phase RT-PCR and RT in situ PCR for HCV RNA in HCV infected patients
pp. 105-105(1)
Authors: Simon Z.; Lotz G.; Nemes B.; Szalav F.; Lengyel G.; Abonyi M.; Ibranyi E.; Schaff Z.

Biomarkers of oxidative stress in patients with chronic hepatitis C
pp. 105-105(1)
Authors: Serejo F.; Filipe P.; Emerit I.; Freitas J.; Fernandes A.; Ramalho F.; Carneiro de Moura M.

Serological response to infection with different isolates of hepatitis C virus types
pp. 106-106(1)
Authors: Halfon P.; Halimi G.; Khiri H.; Bourliere M.; Ouzan D.; Gerolami V.; Cartouzou G.

Molecular epidemiology of the transmission of hepatitis C virus between vireamic regular spouses
pp. 106-106(1)
Authors: Halfon P.; Bourliere M.; Halimi G.; Cartouzour G.; Gerolami V.; Raabe J.; Renoux C.; Riflet H.; Ouzan D.

Hepatocyte DNA measurement by TV image analysis is patients with chronic C hepatitis
pp. 106-106(1)
Authors: Werling K.; Szalay F.; Molnar B.; Schaff Z.; Tulassay Z.

Peripheral NK cells as the possible prognostic factor in the IFN- treatment of patients with chronic viral hepatitis (CVH) type B & C
pp. 106-106(1)
Authors: Daniluk J.; Lozowski C.T.; Kasztelan-Szczerbinska B.; Gieroba J.

Genetic alterations in the S gene of hepatitis B virus in patients with acute hepatitis B, chronic hepatitis B and hepatitis B cirrhosis before and after liver transplantation
pp. 107-107(1)
Authors: Rodriquez-Frias F.; Buti M.; Jardi R.; Vargas V.; Cotrina M.; Quer J.; Esteban R.; Guardia J.

HCV-related mixed cryoglobulinemia protects against the progression of liver disease
pp. 108-108(1)
Authors: Lenzi M.; Bianchi G.; Muratori L.; Frisoni M.; Lari F.; Propato N.; Cassani F.; Bianchi F.

Rapid detection and clinical significance of mutations in the promoter and the pre-core region of hepatitis B virus genome
pp. 108-108(1)
Authors: Grandjacques C.; Pradat P.; Stuyver L.; Pichoud C.; Maisonnas M.; Trepo C.; Zoulim F.

Patients who acquire hepatitis C early in life have a markedly increased mortality even when cirrhosis is absent at diagnosis and disease duration is short
pp. 108-108(1)
Authors: Niederau C.; Lange S.; Heintges T.; Erhardt A.; Buschkamp M.; Hurter D.; Nawrocki M.; Kruska L.; Hensel F.; Petry W.; Haussinger D.

The HBV trimera mouse: a model for human HBV infection and evaluation of anti-viral agents
pp. 108-108(1)
Authors: Ilan E.; Nussbaum O.; Lubin I.; Eren R.; Ben-Moshe O.; Arazi J.; Berr S.; Neville L.; Shouval D.; Nahor O.; Reisner Y.; Dagan S.; Galun E.

Retreatment of chronic hepatitis C (CHC) with sequential interferon-ribavirin combination (IFN-RIBA) therapy
pp. 109-109(1)
Authors: Chemello L.; Cavalletto L.; Bernardinello E.; Donada C.; Belussi F.; Casarin P.; Urban F.; Pontisso P.; Ruvoletto M.; Alberti A.

Comparison of morbidity and mortality in HBsAg positive cirrhosis with or without hepatitis delta virus superinfection
pp. 109-109(1)
Authors: Giustina G.; Christensen E.; Pantalena M.; Realdi G.; Corrocher R.; Schalm S.; Fattovich G.

A novel hepatitis E (HEV) isolated from a patient with acute nA-C hepatitis in Italy
pp. 109-109(1)
Authors: Romano L.; Tanzi E.; Zanetti A.; Schlauder G.; Desai S.; Dawson G.

Immunogenicity and persistence of the first combined vaccine against hepatitis A and B
pp. 109-109(1)
Authors: Van Damme P.; Beutels M.; Van Herck K.; Thoelen S.; Meheus A.

Personalized versus standard interferon alpha treatment in chronic hepatitis C
pp. 110-110(1)
Authors: Bellobuono A.; Tempini S.; Gelosa F.; Airoldi A.; Mondazzi L.; Ideo G.

Liver iron overload in patients with chronic active hepatitis C. Prevalence, role of the hemochromatosis gene and relation with hepatic histological lesions
pp. 110-110(1)
Authors: Hezode C.; Cazeneuve C.; Coue O.; Lonjon I.; Roudot-Thoraval F.; Bastie A.; Duvoux C.; Pawlotsky J.; Zafrani E.S.; Girodon E.; Dhumeaux D.

Hepatitis viruses and liver failure related deaths in human immunodeficiency virus infected patients
pp. 110-110(1)
Authors: Puoti M.; Spinetti A.; Ghezzi A.; Rossi S.; Forleo M.A.; Zaltron S.; Putzolu V.; Zanini B.; Donisi A.; Tomasoni D.; Carosi G.

A multi-centre, double-blind, parallel-group comparative study to assess the efficacy and safety of a single dose of either Hepagene&unknown; or Engerix(R)B in subjects with an inadequate response to previous vaccination with an S-containing hepatitis B vaccine
pp. 110-110(1)
Authors: Williams A.; Young M.

HBV polymerase mutations associated with resistance to lamivudine and famciclovir do not decrease sensitivity to adefovir
pp. 111-111(1)
Authors: Gibbs C.; Flores C.; Yang H.; Westland C.; Toole J.; Xiong X.

Emergence of lamivudine resistant HBV is not always associated with HBeAg positive status or a high pretreatment viral load in patients with chronic infection
pp. 111-111(1)
Authors: Whalley S.; Manolakopoulos S.; Brown D.; Davies S.; Ling R.; Harrison T.; Dusheiko G.

Development of different anti-HCV antibodies with different staining patterns
pp. 111-111(1)
Authors: Roskams T.; Depla E.; Buyse M.; Maertens G.; Van Damme B.; Desmet V.

Long-term follow-up of sustained responders to interferon therapy
pp. 111-111(1)
Authors: Reichard O.; Glaumann H.; Weistal R.; Norkrans G.; Fryden A.; Weiland O.

Significant improvement of virological response after ribavirin addition to IFN in still viremic patients after the initial month of IFN therapy for chronic hepatitis C
pp. 112-112(1)
Authors: Bellobuono A.; Tempini S.; Mondazzi L.; Di Napoli M.; Ideo G.

The HCV-genotype does not predict mortality, complications and incidence of liver cancer
pp. 112-112(1)
Authors: Niederau C.; Lange S.; Heintges T.; Erhardt A.; Buschkamp M.; Hurter D.; Nawrocki M.; Kruska L.; Hensel F.; Petry W.; Haussinger D.

Long-term follow-up of chronic hepatitis B patients after interferon treatment
pp. 112-112(1)
Authors: Honkoop P.; Hansen B.; Ashruf R.; de Man R.; Schalm S.

HLA genes and chronic hepatitis C severity
pp. 112-112(1)
Authors: Asti M.; Martinetti M.; Zavaglia C.; Cuccia M.; Bruno S.; Cividini A.; Ideo G.; Mondelli M.U.; Silini E.

The cost-effectiveness of prolonged alfa interferon for chronic hepatitis C in Spain
pp. 113-113(1)
Authors: Buti M.; Casado M.A.; Fosbrook L.; Esteban R.

Human immunodeficiency virus infection does not alter T cell immune response to hepatitis C
pp. 113-113(1)
Authors: Woitas R.P.; Rockstroh J.K.; Luers C.; Sauerbruch T.; Spengler U.

Long-term immunogenicity of a high potency inactivated hepatitis A vaccine
pp. 113-113(1)
Authors: Van Damme P.; Van Herck K.; Thoelen S.; Meheus A.

Famciclovir treatment in lamivudine resistent chronic hepatitis B patients
pp. 113-113(1)
Authors: Wolters L.; Honkoop P.; de Man R.; Niesters H.; Schalm S.

Interferon alfa therapy for the anti-HBe positive form of chronic hepatitis B: increased efficacy of a two years course
pp. 114-114(1)
Authors: Puoti M.; Forleo M.A.; Rossi S.; Zaltron S.; Spinetti A.; Putzolu V.; Zanini B.; Carosi G.

Response to triple antiviral therapy in interferon non-responders with chronic hepatitis C
pp. 114-114(1)
Authors: Brillanti S.; Foli M.; Di Tomaso M.; Gramantieri L.; Masci C.; Bolondi L.

Randomised trial in HBeAg negative chronic hepatitis B of oral nucleoside analogues in combination with interferon
pp. 114-114(1)
Authors: Alexopoulou A.; Zafiropoulou E.; Papakonstantinou A.; Hadziyannis S.J.

Famciclovir treatment of hepatitis B infection in patients with end-stage liver disease
pp. 114-114(1)
Authors: Manns M.; Neuhaus P.; Schoenborn H.; Griffin K.E.

MxA mRNA as early predicter of response to interferon therapy in chronic hepatitis C
pp. 115-115(1)
Authors: Nava M.C.; Simeoni E.; Panizzuti F.; Redaelli A.; Turriziani O.; Ogliari C.; Quarenghi C.; Scalori A.; Pozzi M.; Pioltelli P.; Roffi L.; Mancia G.; Antonelli G.

Do serum HCV RNA titers predict the severity of liver disease in HCV carriers with normal ALT levels?
pp. 115-115(1)
Authors: Puoti C.; Stati T.; Magrini A.

Predictive value of viral load monitoring in chronic hepatitis B virus infection treated with interferon-
pp. 115-115(1)
Authors: Nagata I.; Gregorio G.; Colucci G.; Williams R.; Mieli-Vergani G.; Vergani D.

Prolonged therapy of recurrent hepatitis B-infection after liver transplantation with nucleoside analogues
pp. 115-115(1)
Authors: Jaeckel E.; Tillmann H.; Krueger M.; Schmidt H.; Boeker K.; Trautwein C.; Nashan B.; Bruns I.; Manns M.

Famciclovir improves liver histology in immunosuppressed patients with chronic hepatitis B
pp. 116-116(1)
Authors: Wedemeyer H.; Boeker K.; Pethig K.; Flemming P.; Vollmar J.; Griffin K.; Haverich A.; Manns M.

Open -IFN treatment of chronic HBV/HCV hepatitis in heart transplant (HTx) recipients
pp. 116-116(1)
Authors: Minniti F.; Pevere S.; Graziotto A.; Burra P.; Chiaramonte M.; Livi U.; Naccarato R.; Fagiuoli S.

Interferon alpha enhances soluble TNF receptor-I levels independently of interleukin-10 and TNF
pp. 116-116(1)
Authors: Pirisi M.; Del Forno M.; Fabris C.; Falleti E.; Toniutto P.; Vitulli D.; Maurizio R.; Gonano F.; Bartoli E.

Induction of endogenous interferon- and reduction of viremia during hemodialysis in uremic patients with chronic hepatitis C
pp. 116-116(1)
Authors: Sampietro M.; Como G.; Catania A.; Badalamenti S.; Lunghi G.; Orlandi A.; Corbetta N.; Finazzi S.; Carlin A.; Graziani G.; Ponticelli C.; Fiorelli G.

The severity of histologic lesions is not related to liver HCV RNA level in patients with chronic hepatitis C
pp. 117-117(1)
Authors: Gervais A.; Martinot M.; Boyer N.; Pouteau M.; Castelnau C.; Degott C.; Erlinger S.; Marcellin P.

Evolution of risk factors and characteristics of patients with chronic hepatitis C between 1990 and 1997 in an urban area in France
pp. 117-117(1)
Authors: Bastie A.; Foury M.; Hezode C.; Lonjon I.; Metreau J.M.; Douvin C.; Mallat A.; Dhumeaux D.; Roudot-Thoraval F.

Timing and dose effect of alpha-interferon on early viral kinetics in chronic hepatitis C
pp. 117-117(1)
Authors: Ruvoletto M.; Pontisso P.; Casarin C.; Migliorato I.; Chemello L.; Cavalletto L.; Alberti A.

Efficacy of 3 vs. 5 MU IFN-alpha given daily followed by a tiw maintenance regimen in chronic hepatitis C: a randomized trial
pp. 117-117(1)
Authors: Hadziyannis A.; Papaioannou C.; Spanou E.; Manesis E.; Hadziyannis S.

A multi-centre, double-blind, parallel-group comparative study to assess the efficacy and safety of Hepagene&unknown; and Engerix(R)B in subjects with an proven inadequate response to prior vaccination
pp. 118-118(1)
Authors: Williams A.; Young M.

Long term hystological response to interferon treatment in patients with chronic hepatitis C
pp. 118-118(1)
Authors: Divincenzo A.; Loria P.; Piani D.; Bagni A.; Bertolotti M.; Concari M.; Martella P.; Carulli N.

Prediction of resistance to interferon therapy in chronic hepatitis C patients based on bile acid composition in liver and serum. Preliminary results
pp. 118-118(1)
Authors: Rodriques C.M.P.; Brites D.; Serejo F.; Costa A.; Ramalho F.; Moura M.C.

Early decrease of the viremia with ribavirin and interferon combination therapy in patients with chronic hepatitis C non responders to the interferon
pp. 118-118(1)
Authors: Vega P.; Hermida M.; Castro A.; Calvo S.L.; Balinas J.; Torron R.; Pedreira J.

Are HLA B8,DR3, HLA DQ2 predisposing factors for chronicity in hepatitis C virus (HCV) infection and negative predictors of response to interferon-2b?
pp. 119-119(1)
Authors: Par A.; Paal M.; Horanyi M.; Mozsik G.

Serum ratio of -GT/ALT activity rather than ISDR variability is predictive for virological responsiveness to IFN- therapy in patients infected by HCV genotypes 1A, 1B, and 3A
pp. 119-119(1)
Authors: Mihm S.; Monazahian M.; Grethe S.; Fechner C.; Ramadori G.; Thomssen R.

Preferentially high prevalence of hepatitis G virus (HGV) infection as compared to HCV infection in patients undergoing chronic hemodialysis
pp. 119-119(1)
Authors: Sheng L.; Widyastuti A.; Kosala H.; Donck J.; Vanrenterghem Y.; Setijoso E.; Soumillion A.; Verslype C.; Schelstraete R.; Emonds M.-P.; Hess G.; Yap S.H.

Effect of a high induction dose (10 MU/TIW) of -interferon (-IFN) compared to a 5 MU/TIW dose in the treatment of chronic hepatitis C: an interim report
pp. 119-119(1)
Authors: Puglisi L.; Buzzi A.; Matera A.; Marino P.; Pompili M.; Rapaccini G.; Grieco A.; Gasbarrini G.

Evolution of hepatitis C in children with HCV vertically transmitted
pp. 120-120(1)
Authors: Minola E.; Berera F.; Fracassetti O.; Tambini R.; Qunzan G.; Persiani P.; Vicari O.; Colombo A.; Paris B.

Interferon versus ribavirin plus interferon in chronic hepatitis C patients relapsers and non responders to recombinant interferon
pp. 120-120(1)
Authors: Vandelli C.; Renzo F.; Lovato E.; Sardini C.; Di Marco G.; Tisminetzky S.; Ventura E.

Long term protection in mentally retarded vaccinated against hepatitis B: results after 11 years
pp. 120-120(1)
Authors: Vellinga A.; Van Damme P.; Vranckx R.; Weyler J.; Meheus A.

Prevalence of hepatitis G virus (HGV) RNA and of anti-E2 antibody in various populations at low or high risk of transmitted viruses
pp. 120-120(1)
Authors: Roudot-Thoraval F.; Morand-Joubert L.; Brossard Y.; Mariotti M.; Parnet M.; Girot R.; Loiseau P.; Lefrere J.J.

Can interferon-ribavirin effectively treat patients who did not respond to a first conventional therapy by interferon ?
pp. 121-121(1)
Authors: Marchi S.; Ciccorossi P.; Petruccelli S.; Ricchiuti A.; Arpe P.; Da Massa Carrara P.; Costa F.; Bellini M.; Maggi F.; Vatteroni M.L.; Bendinelli M.; Maltinti G.

Interleukin-12 (IL-12) treatment in chronic hepatitis C
pp. 121-121(1)
Authors: Teuber G.; Berg T.; Rodig S.; Caspary W.F.; Hopf U.; Zeuzem S.

Patient to patient transmission of hepatitis C virus during gastroscopy on neuroleptanalgesia
pp. 121-121(1)
Authors: Crenn P.; Gigou M.; Passeron J.; Dussaix E.; Bismuth H.; Feray C.

Sustained clearance of HCV RNA after treatment of HCV recurrence with IFN-ribavirin combination
pp. 121-121(1)
Authors: Bizollon T.; Ducerf C.; Chevallier M.; Baulieux J.; Trepo C.

Sequential versus concomitant administration of ribavirin and interferon alfa-N3 in patients with chronic hepatitis C not responding to interferon alone. Results of a randomized controlled trial
pp. 122-122(1)
Authors: Sostegni R.; Rizzetto M.; Ghisetti V.; Pittaluga F.; Marchiaro G.; Rocca G.; Borghesio E.; Saracco G.

Alpha IFN plus ketoprofen versus IFN alone in naive patients with chronic hepatitis C (CH&unknown;C)
pp. 122-122(1)
Authors: Fabris P.; Benedetti P.; Stecca C.; Tositti G.; Bettini C.; Carlotto A.; Rassu M.; Infantolino D.; Pellizzer G.P.; de Lalla F.

Alpha-interferon induces HBeAg- chronic active liver disease but improves long-term survival in HBeAg+ chronic active hepatitis patients
pp. 122-122(1)
Authors: Koek G.; Horsman Y.; Geubel A.; Fevery J.; Nevens F.

Long-term persistence of HBV DNA in chronic hepatitis patients successfully treated with interferon
pp. 122-122(1)
Authors: Cianciara J.; Radkowski M.; Loch T.; Kozlowska J.; Cybula A.

Ribavirin and interferon retreatment of HCV chronic patients non responder to interferon
pp. 123-123(1)
Authors: De Bac C.; Pastore G.; Piccinino F.; Badolato M.; Tosti M.; Osso A.; Milella M.; Santantonio T.; Calabria G.; Felaco F.; Gaeta G.; Stornaiuolo G.; Taliani G.

Apoptosis and bile duct cell dysplasia in patients with primary sclerosing cholangitis (PSC) with and without cholangiocarcinoma (CC)
pp. 124-124(1)
Authors: Bergquist A.; Glaumann H.; Stal P.; Wang G.; Broome U.

CTLA-4 gene polymorfism associated with primary sclerosing cholangitis (PSC)
pp. 124-124(1)
Authors: Saarinen S.; Broome U.; Liger A.; Olsson R.; Hultcrantz R.; Olerup O.

Organ and cellular distribution of the organic anion transporting polypeptide 2 (oatp2) in rat
pp. 124-124(1)
Authors: Gao B.; Stieger B.; Meier P.J.

Osmotic regulation of the heat shock response in primary rat hepatocytes
pp. 124-124(1)
Authors: Kurz A.K.; Schliess F.; Haussinger D.

LPS induces cholestasis by vesicular accumulation and downregulation of the multidrug resistance protein2
pp. 125-125(1)
Authors: Kubitz R.; Warskulat U.; Kurz A.K.; Keppler D.; Haussinger D.

Evidence for carrier-mediated bilirubin transport across the basal plasma membrane of human placenta trophoblast at term
pp. 125-125(1)
Authors: Pascolo L.; Bayon J.E.; Serrano M.A.; Ostrow D.; Tiribelli C.; Gonzalez-Gallego J.; Marin J.G.

Biochemical and functional characterization of the coenzyme A (CoA) pools in rats with long-term cholestasis
pp. 125-125(1)
Authors: Krahenbuhl S.; Ledermann M.; Krahenbuhl L.

Bile acid composition of amniotic fluid and maternal serum in cholestasis of pregnancy and effect of ursodeoxycholic acid
pp. 125-125(1)
Authors: Brites D.; El-Mir M.; Rodrigues C.; van-Zeller H.; Marin J.

Ursodeoxycholic acid complexation with 2-hydroxypropyl--cyclodextrin increases ursodeoxycholic acid biliary excretion after single oral administration in rats
pp. 126-126(1)
Authors: Ventura P.; Panini R.; Montosi G.; Garuti C.; Vandelli M.A.; Brunetti G.; Pietrangelo A.; Salvioli G.

Excretion of bile acids in colostrum from patients with intrahepatic cholestasis of pregnancy is decreased after ursodeoxycholic acid therapy
pp. 126-126(1)
Authors: Brites D.; Rodrigues C.; Cardoso C.; Graca L.

Human liver ADH -isoenzyme is the sole cytosolic 3-hydroxysteroid dehydrogenase of iso-bile acids
pp. 126-126(1)
Authors: Marschall H.; Oppermann U.; Svensson S.; Persson B.; Hoog J.; Jornvall H.

Cyclosporin cholestasis is worsened by verapamil, a p-glycoprotein (p-GP) inhibitor, in the isolated perfused rat liver (IPRL)
pp. 126-126(1)
Authors: Delle Monache M.; Gigliozzi A.; Fraioli F.; Romeo R.; Benedetti A.; Marucci L.; Jezequel A.M.; Alvaro D.

Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man
pp. 127-127(1)
Authors: Rust C.; Sauter G.; Oswald M.; Buttner J.; Kullak-Ublick G.A.; Paumgartner G.; Beuers U.

Effects of serpins on cholesterol crystallization in model bile
pp. 127-127(1)
Authors: Janciauskiene S.; Lindgren S.

Incidence of hepatic and extrahepatic malignancies in primary biliary cirrhosis (PBC)
pp. 127-127(1)
Authors: Floreani A.; Chiaramonte M.; Baragiotta A.; Naccarato R.

Adenosine, via A₁ receptors, counteracts glucagon choleresis in the isolated perfused rat liver (IPRL)
pp. 127-127(1)
Authors: Gigliozzi A.; Delle Monache M.; Fraioli F.; Romeo R.; Alvaro D.

P53 mutations in dysplastic and neoplastic bile duct epithelium in primary sclerosing cholangitis
pp. 128-128(1)
Authors: Vautier G.; Portmann B.; Bomford A.; Jenkins D.; Ryder S.

Methotrexate for treatment of primary sclerosing cholangitis. A placebo-controlled cross-over trial
pp. 128-128(1)
Authors: Rasmussen H.H.; Tage-Jensen U.; Vyberg M.; Schlichting P.; Schaffalitzky de Mucadell O.; Bonnevie O.

Study of the immunophenotype of 44 intra- or extra-hepatic cholangiocarcinomas
pp. 128-128(1)
Authors: Rullier A.; Winnock M.; Fawaz R.; Balabaud C.; Bioulac-Sage P.; Le Bail B.

Osmolyte-strategy of Ito-cells during their transformation into myofibroblasts
pp. 128-128(1)
Authors: Peters-Regehr T.; Bode J.G.; Kubitz R.; Haussinger D.

Obesity and not alcohol intake is the main cause of liver steatosis
pp. 129-129(1)
Authors: Bellentani S.; Saccoccio G.; Masutti F.; Croce L.; Tiribelli C.

Steroids vs enteral nutrition in severe alcoholic hepatitis. Interim results of a prospective, randomized, multicentric trial
pp. 129-129(1)
Author: Cabre E.

Intraportal acetylcholine reverses insulin resistance caused by chronic bile duct ligation
pp. 129-129(1)
Authors: Lautt W.W.; Xie H.

Effect of serotonin on cell volume regulation in resting early culture rat hepatic stellate cells
pp. 129-129(1)
Authors: Fischer T.; Schworer H.; Raddatz D.; Knittel T.; Saile B.; Ramadori G.

Sources of benzodiazepine-like compounds: food and bacterial flora
pp. 130-130(1)
Authors: Avallone R.; Venturini I.; Corsi L.; Farina F.; Di Bella M.; Zeneroli M.L.; Baraldi M.

Polymorphism in the interleukin-10 (IL-10) promoter is associated with fibrotic alcoholic liver disease
pp. 130-130(1)
Authors: Grove J.; Daly A.K.; Bassendine M.F.; Day C.P.

Influence of iron on the specificity and sensitivity of carbohydrate-deficient transferrin (CDT)
pp. 130-130(1)
Authors: De Feo T.M.; Fargion S.; Duca L.; Mattioli M.; Cappellini M.D.; Fiorelli G.

Taurousodeoxycholic acid reduces ethanol-induced cytotoxicity by preventing mitochondrial glutathione depleton in Hep G2 cells
pp. 130-130(1)
Authors: Neuman M.; Shear N.; Bellentani S.; Tiribelli C.

Paradoxical protection against experimental alcoholic liver disease by disulfiram despite high acetaldehyde levels
pp. 131-131(1)
Authors: Lindros K.O.; Jokelainen K.; Nanji A.

Iron content of alcoholic fatty liver does not predict progression to fibrotic disease
pp. 131-131(1)
Authors: Day C.P.; James O.F.W.; Guzail M.; Burt A.D.

Growth hormone secretagogue ipamorelin reduces the hepatic catabolic stress response during steroid treatment
pp. 131-131(1)
Authors: Grofte T.; Skjaerbaek C.; Johansen P.B.; Malmlof K.; Haahr P.M.; Orskov H.; Vilstrup H.

Pain is a hepatic catabolic stimulus in normal man
pp. 131-131(1)
Authors: Greisen J.; Grofte T.; Hansen P.O.; Vilstrup H.

Morphological features of amoxycillin-clavulanate-induced hepatitis : an experience based on 27 biopsied cases
pp. 132-132(1)
Authors: Sempoux C.; Horsmans Y.; Hautekeete M.; Geubel A.; Rahier J.

Hepatic oxidative injury induced by leukotriene D₄ and prevention by S-adenosylmethionine
pp. 132-132(1)
Authors: Cincu R.; Rodriguez-Ortigosa C.M.; Ruiz F.; Avila M.A.; Quiroga J.; Mato J.M.; Prieto J.

Ursodeoxycholic acid increases the more active isoform of methionine adenosyltransferase, a key enzyme in hepatic glutathione production
pp. 132-132(1)
Authors: Cincu R.; Rodriguez-Ortigosa C.M.; Ruiz F.; Avila M.A.; Quiroga J.; Mato J.M.; Prieto J.

Ciprofloxacin medication decreases ethanol elimination rate in man
pp. 132-132(1)
Authors: Tillonen J.; Homann N.; Salaspuro V.; Salaspuro M.

Visualization of post-ischemic free radicals formation in livers isolated from rats chronically exposed to ethanol
pp. 133-133(1)
Authors: Gasbarrini A.; Addolorato G.; Simoncini M.; Pasini P.; Nardo B.; Franceschi F.; De Luca A.; Vagni G.; Roda E.; Pola P.; Bernardi M.; Roda A.; Gasbarrini G.

Insulin resistance and postprandial hyperinsulinemia in nonalcoholic steatohepatitis
pp. 133-133(1)
Authors: Tankurt E.; Biberoglu S.; Hekimsoy Z.; Ellidokuz E.; Kupelioglu A.

Isolated hyperferritinemia is associated with liver iron overload, liver steatosis and dyslipidemia
pp. 133-133(1)
Authors: Vigano M.; Vergani A.; Parma L.; Malosio I.; Salvioni A.; Caronni N.; Arosio V.; Bovo G.; Arosio C.; Piperno A.

Hepatic glycogen metabolism in rats with biliary cirrhosis after Y-en-Roux anastomosis
pp. 133-133(1)
Authors: Krahenbuhl L.; Hagenbuch B.; Schafer M.; Krahenbuhl S.

Octreotide in cirrhotic patients
pp. 134-134(1)
Authors: Ottesen L.H.; Flyvbjerg A.; Moller S.; Bendtsen F.

Elevation of the tryptophan catabolic pathway metabolite quinolinic acid in liver cirrhosis
pp. 134-134(1)
Authors: Look M.P.; Berthold H.K.; Kreuzer K.A.; Riezler R.; Sauerbruch T.

Enhancement of bile acid synthesis and secretion by epomediol in the rat
pp. 134-134(1)
Authors: Mauriz J.L.; Cuevas M.J.; Collado P.S.; Almar M.; Gonzalez-Gallego J.

Diagnostic value of histochemical stains for copper in Wilson's disease
pp. 134-134(1)
Authors: Pilloni L.; Lecca S.; Van Eyken P.; Demelia L.; Pilleri G.; Nurchi A.; Farci A.; Ambu R.; Callea F.; Faa G.

Cerebral near infrared spectroscopy (NIRS): a novel method for the measurement of indocyanine green (ICG) elimination in the assessment of patients with liver disease
pp. 135-135(1)
Authors: Therapondos G.; Peters C.; Teig M.; Stanley A.; Plevris J.; Hayes P.

Are alcoholic liver disease and fatty liver consequences of an abnormal hepatic steroid metabolism ?
pp. 135-135(1)
Authors: Saksena S.; Wood P.; Stewart P.; Elias E.

S-adenosyl-L-methionine (SAMe) reduces ethanol-induced mitochondrial toxicity and membrane damage in Hep G2 cells
pp. 135-135(1)
Authors: Concari M.; Rebecchi B.; Guicciardi M.; Carubbi F.; Loria P.; Fantin A.B.; Carulli N.

Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels
pp. 135-135(1)
Authors: Vitek L.; Jirsa M.; Machova M.; Brodanova M.; Kalab M.; Marecek Z.; Danzig V.; Kotal P.

Drug-induced acute hepatitis
pp. 136-136(1)
Authors: Kubicka J.; Kryczka W.; Zarebska-Michaluk D.; Dutkiewicz E.

Changes in hepatic fatty acid metabolism in rats with biliary cirrhosis are reflected in the carnitine pool
pp. 136-136(1)
Authors: Wachter S.; Krahenbuhl L.; Krahenbuhl S.

Elevated serum dolichols in cholestatic liver diseases
pp. 136-136(1)
Authors: Humaloja K.; Salaspuro M.; Roine R.P.; Farkkila M.; Vuoristo M.

Amino acid release from skeletal muscle in rats after partial hepatectomy - a microdialysis study
pp. 136-136(1)
Authors: Cervinkova Z.; Zivna H.; Zivny P.; Palicka V.; Vavrova J.

Somatic hypermutation, clonal diversity and preferential expression of the V_H 51p1/V_L kv 325 immunoglobulin gene combination in HCV-associated immunocytomas
pp. 137-137(1)
Authors: Pozzato G.; Zorat F.; Fanni M.; Baracetti S.; Mazzoran L.; Mazzaro C.; Burrone O.R.; Efremov D.G.

Autoimmune LKM1 targets CYP2D6 on the plasmamembrane of isolated rat hepatocytes: a confocal study
pp. 137-137(1)
Authors: Muratori L.; Parola M.; Ripalti A.; Lenzi M.; Bellomo G.; Carini R.; Landini M.; Albano E.; Bianchi F.

IL-12 as an adjuvant for the induction of immune responses against hepatitis C viral antigens
pp. 137-137(1)
Authors: Lasarte J.; Casares N.; Lopez-Diaz de Cerio A.; Ruiz J.; Cheng O.; Xiaoming X.; Bruna O.; Borras-Cuesta F.; Prieto J.

Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection
pp. 137-137(1)
Authors: Gregorio G.; Pensati P.; Iorio R.; Vegnente A.; Mieli-Vergani G.; Vergani D.

Combined immunosuppressive therapy with azathioprine and prednisone in patients with primary sclerosing cholangitis - a pilot study
pp. 138-138(1)
Authors: Schramm C.; Pascher E.; Helmreich-Becker I.; Gerken G.; Meyer zum Buschenfelde K.H.; Lohse A.W.

A novel assay for detecting antibodies to cytochrome P4502D6, the molecular target of liver kidney microsomal antibody type 1
pp. 138-138(1)
Authors: Kerkar N.; Ma Y.; Hussain M.; Muratori L.; Bianchi F.; Mieli-Vergani G.; Vergani D.

Actin is not likely to be the major target of autoimmune hepatitis type 1 (AIH-1)-associated perinuclear anti neutrophil cytoplasmic antibodies (pANCA)
pp. 138-138(1)
Authors: Grassi A.; Zauli D.; Fusconi M.; Cassani F.; Ghetti S.; Ballardini G.; Bianchi F.

PBC prevalence is increasing. Geographic variations are probably ''real''
pp. 138-138(1)
Authors: Metcalf J.; Howel D.; Bhopal R.; James O.F.W.

Is primary sclerosing cholangitis an HLA class I associated disease ?
pp. 139-139(1)
Authors: Moloney M.; Underhill J.; Thomson L.; Strettell M.; Clare M.; Williams R.; Donaldson P.

Autoimmune acute hepatitis: an underrecognized liver disease
pp. 139-139(1)
Authors: Ganne-Carrie N.; Christidis C.; Tordjmann T.; Grimbert S.; Trinchet J.; Guettier C.; Beaugrand M.

SLA positive autoimmune hepatitis (AIH) behaves clinically, histologically and biochemically as ANA positive AIH
pp. 139-139(1)
Authors: Kanzler S.; Weidemann C.; Gerken G.; Lohr H.; Meyer zum Buschenfelde K.; Lohse A.

Definition of a novel CYP2D6 epitope in autoimmune hepatitis type 2 and in chronic hepatitis C
pp. 139-139(1)
Authors: Obermayer-Straub P.; Sugimura T.; Braun S.; Luttig B.; Loges S.; Kayser A.; Durazzo M.; Strassburg C.; Manns M.P.

Autoantibodies to uroporphyrinogen decarboxylase in patients with porphyria cutanea tarda
pp. 140-140(1)
Authors: Ma Y.; Fracanzani A.L.; Fiorelli G.; Williams R.; Fargion S.; Vergani D.

F actin autoantibodies in patients with hepatitis and gluten sensitive enteropathy
pp. 140-140(1)
Authors: Clemente M.; Bernasconi M.; Arcadu F.; Frau F.; Corpino M.; Ciccotto L.; Pilleri G.; De Virgiliis S.

Vitamin D receptor gene polymorphism and bone mass in primary biliary cirrhosis
pp. 140-140(1)
Authors: Pares A.; Guanabens N.; Martinez de Osaba M.; Oriola J.; Pons F.; Monegal A.; Salvado G.; Peris P.; Rivera F.; Rodes J.

Interferon therapy in LKM1 positive patients with chronic hepatitis C : follow-up by a quantitative radioligand assay for CYP2D6 antibody detection
pp. 140-140(1)
Authors: Duclos-Vallee J.C.; Nishioka M.; Hosomi N.; Arima K.; Leclercq A.; Bach J.F.; Yamamoto A.M.

Soluble fas, TNF-RI and TNF-RII in hepatitis C virus infection with and without extrahepatic manifestations
pp. 141-141(1)
Authors: Realdon S.; Pontisso P.; Adami F.; Trentin L.; Noventa F.; Agostini C.; Alberti A.

The costimulatory effects of IL-12 on the HBV-induced immune response depend on the serological status but not on the stage of liver disease
pp. 141-141(1)
Authors: Tully G.A.; Lohr H.F.; Gerken G.; Meyer zum Buschenfelde K.-H.; Schlaak J.F.

IgM and IgG productions are inhibited by bile acids by a proliferation-dependent mechanism
pp. 141-141(1)
Authors: Correia L.; Podevin P.; Borderie D.; Conti F.; Poupon R.; Calmus Y.

Treatment of liver metastases of colon cancer with adenovirus expressing IL-12
pp. 142-142(1)
Authors: Mazzolini G.; Herraiz M.; Qian C.; Xie X.; Drodzik M.; Sun Y.; Prieto J.

Long term liver directed gene therapy by downregulating the anti adenovirus Th1 immune response
pp. 142-142(1)
Authors: Ilan Y.; Sauter B.; Chowdhury N.R.; Davidson A.; Horwitz M.S.; Chowdhury J.R.

Elevated serum type IV collagen: a sensitive marker of severe fibrosis / cirrhosis in haemochromatosis
pp. 142-142(1)
Authors: George D.; Ramm G.; Walker N.; Powell L.; Crawford D.

Increased frequency of C4Q0 variants in patients with HCV-related mixed cryoglobulinemia
pp. 142-142(1)
Authors: Lenzi M.; M Frisoni M.; Mantovani V.; Muratori L.; Cortelazzo A.; Cuccia M.; Bianchi F.

CD8⁺ cells in liver and expression of hereditary haemochromatosis (HH)
pp. 143-143(1)
Authors: Cardoso E.M.P.; de Sousa M.; Hultcrantz R.

Normal beta-2-microglobulin (2m) gene in patients with hemochromatosis and no evidence of linkage to chromosome 6
pp. 143-143(1)
Authors: Sampietro M.; Lupica L.; Corbetta N.; Amato M.; Casatta A.; Pizzuti A.; Laurenzi L.; Fargion S.; Fiorelli G.

Vasoactive compounds increase the efficiency of adenoviral gene transfer to primary liver tumors
pp. 143-143(1)
Authors: Bilbao R.; Qian C.; Drozdzik M.; Pajares M.J.; Prieto J.

MHC class-I associations in iron overload: new link between the H63D mutation, HLA-A29 and ''non-classical'' haemochromatosis
pp. 143-143(1)
Authors: Porto G.; Alves H.; Rodrigues P.; Cabeda J.; Portal C.; Ruivo A.; Justica B.; Wolff R.; De Sousa M.

Swedish patients with hemochromatosis (HH) have low levels of iron and a low frequency of cirrhosis
pp. 144-144(1)
Authors: Hagen K.; Befrits R.; Cardoso E.M.P.; Stal P.; Hultcrantz R.

Redox gene therapy of liver ischemia/reperfusion injury reduces AP-1 and NF-KB activation
pp. 144-144(1)
Authors: Zwacka R.M.; Zhang Y.; Halldorson J.; Dudus L.; Engelhardt J.F.

Genotype versus phenotype of 1-antitrypsin in family studies
pp. 144-144(1)
Authors: Topic E.; Zuntar I.; Tesija A.; Jurcic Z.; Cekada S.; Antoljak N.; Stefanovic M.

HLA-H mutations in patients with chronic hepatitis C
pp. 144-144(1)
Authors: Ferenci P.; Datz C.; Kazemi-Shirazi L.; Hackl W.; Maier-Dobersberger T.; Polli C.; Kaserer K.; Osterreicher C.; Steindl P.; Wrba F.; Penner E.

Prevalence of HFE mutations in patients with iron overload and in control subjects from the general belgian population
pp. 145-145(1)
Authors: Dahan K.; Horsmans Y.; Lambot V.; Geubel A.; Verellen-Dumoulin C.

Mutations in the hemochromatosis gene and response to interferon in chronic hepatitis C
pp. 145-145(1)
Authors: Sampietro M.; Corbetta N.; Amato M.; Casatta A.; Lupica L.; Mattioli M.; Del Vitto M.; Molteni V.; Fracanzani A.L.; Fargion S.; Fiorelli G.

Effects of therapeutic phlebotomies on genetic hemochromatosis regarding a French national epidemiologic study on a sample of 498 patients
pp. 145-145(1)
Authors: Didelot J.; Blanc P.; Martinez P.; Larrey D.; Michel H.

The delivery of antiviral genes to hepatitis B virus infected liver cells by baculovirus vectors
pp. 145-145(1)
Authors: Errington W.; McIntosh E.D.G.; Thomas H.C.; McGarvey M.

HFE gene mutations and alcohol intake are main determinants of liver iron overload in male patients with chronic viral hepatitis
pp. 146-146(1)
Authors: Vergani A.; Vigano M.; Malosio I.; Fossati L.; Arosio C.; Trombini P.; Ricci A.; Bovo G.; Boari G.; Piperno A.

Development of recombinant adenoviral vectors: determination of the transduction efficiency and duration of transgene expression in colorectal cancer cells
pp. 146-146(1)
Authors: Heinicke T.; Hemmi S.; Mauer D.; Sauerbruch T.; Caselmann W.H.

Prevalence of the haemochromatosis gene mutation in non-cirrhotic liver with hepatocellular carcinoma
pp. 146-146(1)
Authors: Bralet M.-P.; Degott C.; Belghiti J.; Terris B.

Arterio-venous shunting in the metastatic liver: evaluation and clinical implications
pp. 147-147(1)
Authors: Bar F.; Battista S.; Bucchi M.C.; Gariboldi A.; Miraglia S.; Zanon C.; Alabiso O.; Molino G.

Red blood cells (RBC) promote a prostaglandin mediated increase in porto-hepatic resistance (PHR) in the isolated and perfused liver
pp. 147-147(1)
Authors: Garcia-Pagan J.; Zhang J.; Clemens M.

Transplantation of conditionally immortalized hepatocytes into the spleen of syngeneic hosts-the mechanism of short term survival
pp. 147-147(1)
Authors: Kim B.; Park J.; Dong S.; Kim H.; Chang Y.; Lee J.; Chang R.

Hepatic heterogeneity in the response to ATP studied in the bivascularly perfused rat liver
pp. 147-147(1)
Authors: Minguetti-Camara V.C.; Constantin J.; Suzuki-Kemmelmeier F.; Ishii-Iwamoto E.L.; Bracht A.

Influence of sex, age and body mass index on serum alt level in healthy blood donors
pp. 148-148(1)
Authors: Leclercq I.; Horsmans Y.; De Bruyere M.; Geubel A.

CO₂ portography-investigation of choice in portal vein assessment?
pp. 148-148(1)
Authors: Patch D.; Tibballs J.; Dodge G.; Papatheodoridis G.; Goulis Y.; Watkinson A.; Burroughs A.

Vaccination against hepatitis B virus: evaluation of the need for booster doses
pp. 148-148(1)
Authors: Stucchi R.S.B.; Lazarini M.S.K.; Zen G.C.; Goncales F.L.

Treatment of dactinomycin induced hepatic veno-occlusive disease (VOD) with prostaglandin E1 (PG E1)
pp. 148-148(1)
Authors: Robberecht E.; Dhooge C.; Van Winckel M.; Laureys G.; Benoit Y.

[Ca²⁺]_i transient and contraction of isolated rat ventricular myocytes arenhanced by sera of patients treated with interferon -2b
pp. 149-149(1)
Authors: Petelenz M.; Janiak R.; Musialik J.; Lewartowski B.; Mazur W.; Strzalka B.; Miasko A.; Gonciarz Z.

Unconjugated bilirubin inhibits glutamate uptake in cortical astrocytes
pp. 149-149(1)
Authors: Silva R.; Mata L.R.; Gulbenkian S.; Pascolo L.; Tiribelli C.; Brites D.

The sensitivity of bile acid synthesis for glutathione is abolished after bile duct ligation
pp. 149-149(1)
Authors: Purucker E.; Marschall H.; Matern S.

Hepatic artery resistance in alcoholic liver disease
pp. 149-149(1)
Authors: Colli A.; Mumoli N.; Conte D.; Cattalini N.; Cocciolo M.

Antibodies to Helicobacter hepaticus in sera from patients with chronic liver disease
pp. 150-150(1)
Authors: Lindgren S.; Nilsson I.; Eriksson S.; Wadstrom T.

Transjugular liver biopsy in the nineties
pp. 150-150(1)
Authors: Papatheodoridis G.; Patch D.; Watkinson A.; Dodge G.; Burrhoughs A.

Familial amyloidotic polyneuropathy as a model for orthotopic domino liver transplantation
pp. 151-151(1)
Authors: Schmidt H.; Propsting M.; Nashan B.; Nakazato M.; Tietge U.; Boker K.; Schlitt J.; Pichlmayr R.; Manns M.

Neutrophil elastase and nitric oxide (NO) during ischemia-reperfusion and their relationships with sICAM-1 and antioxidants
pp. 151-151(1)
Authors: Battista S.; Bar F.; Mengozzi G.; Cerutti E.; Salizzoni M.; Cavalli G.; Nigra M.; Biasi F.; Poli G.; Molino G.

Acute liver failure in children
pp. 151-151(1)
Authors: Pfister E.D.; Melter M.; Rodeck B.; Kardorff R.; Ehrich J.H.H.

Granulocyte colony-stimulating factor (G-CSF) enhances superoxide production in acute liver failure (ALF): an in vivo effect
pp. 151-151(1)
Authors: Clapperton M.; Wendon J.; Rolando N.

Hepatic and serum Fas in acute liver failure due to paracetamol overdose
pp. 152-152(1)
Authors: Tagami A.; Ohnishi H.; Miwa Y.; O'Grady J.; Hughes R.D.

Diazepam clearance and metabolism for the functional assessment of a porcine hepatocyte based bioartificial liver
pp. 152-152(1)
Authors: Como V.; Donini A.; Vianello V.; Risaliti A.; Bonfreschi V.; Gonano C.; Baccarani U.; Pasqualotto A.; Anania G.; Belvedere O.; Degrassi A.; Bresadola F.

Body composition, food intake, and substrate oxidation after liver or kidney transplantation
pp. 152-152(1)
Authors: Roske A.-E.; Hudjetz H.; Schutz T.; Budde K.; Neumayer H.-H.; Lochs H.; Plauth M.

Cardiovascular risk factors (CVRF) and late cardiovascular disease (LCD) in orthotopic liver transplantation (OLT)
pp. 152-152(1)
Authors: Romero M.; Parera A.; Salcedo M.; Duran F.G.; Casariego J.; Carneros J.; Abeytua M.; Cos E.; Clemente G.

Orthotopic liver retransplant (OLReT): incidence and survival
pp. 153-153(1)
Authors: Duran F.; Cercadillo R.; Santos L.; de Diego A.; Salcedo M.; Ferreiroa J.; E Valdecantos; Calleja J.; Clemente G.

Efficacy of lamivudine in patients with hepatitis B virus pre-core mutant infection pre- and post- liver transplantation
pp. 153-153(1)
Authors: Ben-Ari Z.; Zemel R.; Kazatsker A.; Fraser G.; Tur-Kaspa R.

Metabolic evaluation of isolated porcine hepatocytes cultured in human and in pig plasma
pp. 153-153(1)
Authors: Donini A.; Corno V.; Risaliti A.; Bonfreschi V.; Vianello V.; Gonano C.; Anania G.; Pasqualotto A.; Belvedere O.; Degrassi A.; Bresadola F.

Ammonia and 1,4-benzodiazepines in patients with fulminant hepatic failure
pp. 153-153(1)
Authors: Zeneroli M.L.; Venturini I.; Corsi L.; Avallone R.; Farina F.; Ardizzone G.; Centanaro M.; Arrigo A.; Schreier P.; Kleinschnitz M.; Baraldi M.

Diagnosis of biliary complications after liver transplantation (LT) : evaluation with magnetic resonance cholangiography (MR-C)
pp. 154-154(1)
Authors: Pageaux G.; Calvet C.; Taourel P.; Bauret P.; Navarro F.; Burgel J.; Michel J.; Fabre J.; Blanc P.; Domergue J.; Bruel J.; Larrey D.

Laparoscopic hepatectomy in swine. Hemodynamic and biochemical alterations (experimental study)
pp. 154-154(1)
Authors: Pyrsopoulos N.; Smirniotis V.; Kostopanagiotou G.; Papalois A.; Hondroudaki I.; Rigopoulou E.; Elefteriou A.; Tsantoulas D.; Papadimitriou I.

Indication and timing for liver transplantation in idiopathic portal hypertension concerning 6 cases
pp. 154-154(1)
Authors: T. Bizollon T.; J. Dumortier J.; O. Boilot O.; C. Ducerf C.; P. Paliard P.; Trepo C.

Mycophenolate mofetil (MMF) in paediatric liver transplant recipients
pp. 154-154(1)
Authors: Dhawan A.; North-Lewis P.; Heaton AJ Baker N.; Rela M.; Hadzic N.; Srinivasan P.; Mieli-Vergani G.

Helicobacter pylori infection after liver transplantation
pp. 155-155(1)
Authors: Conti F.; Sogni P.; Tuliez M.; Megraud F.; Bernard D.; Dousset B.; Chaussade S.; Calmus Y.

The protective effect of diabetes mellitus on paracetamol induced decrease of liver polyamine salvage pathway
pp. 155-155(1)
Authors: Pavlovic D.; Stojanovic J.; Kocic G.; Bjelakovic G.

Use of color doppler ultrasound and ultrasound contrast in liver transplantation
pp. 155-155(1)
Authors: Como V.; Salcuni M.; Risaliti A.; Pirisi M.; Donini A.; Bulligan M.; Anania G.; Bresadola F.

Conversion to mycophenolate mofetil (MMF) instead of cyclosporine a (CYA) in liver transplant (LT) recipients with renal function impairment. A pilot study
pp. 155-155(1)
Authors: Herrero J.I.; Quiroga J.; Sangro B.; Girala M.; Gomez N.; Beltran A.; Pardo F.; Cienfuegos J.A.; Prieto J.

Veno-occlusive disease (VOD) of the liver presenting in pregnancy: diagnosis by CT imaging of the liver
pp. 156-156(1)
Authors: Ellis A.; Norris S.; Kane P.; Karani J.; Harrison P.; Wendon J.

Predicting outcome following acute rejection of liver allografts
pp. 156-156(1)
Authors: Evrenoglou D.; Palmer C.R.; Tom B.D.M.; Wight D.G.D.; Gimson A.E.; Alexander G.J.M.

The use of 2 mm laparoscope to evaluate bleeding at the trocar site during diagnostic laparoscopy
pp. 156-156(1)
Authors: Badalamenti S.; Jeffers L.; Reddy K.; Molina E.; Mendez P.; Schiff E.

Caroli's disease : study of 6 cases, including 3 of the right hepatic lobe
pp. 156-156(1)
Authors: Fontolliet C.; Gillet M.

A liver with polycysitic liver disease as liver graft for organ transplantation
pp. 157-157(1)
Authors: Glanemann M.; Bechstein W.; Muller A.; Platz K.; Knoop M.; Jones S.; Stange B.; Keck H.; Neuhaus P.

Efficacy of royal jelly and lactulose on thyroxin-induced liver damage in rats
pp. 157-157(1)
Authors: Uzbekova D.; Chugunova L.; Makarova V.; Ryabkov A.; Mirgorodskaya L.

Hepatic adenomata in type Ia glycogen storage disease and liver transplantation: report of a case
pp. 157-157(1)
Authors: Fontolliet C.; Matthieu J.M.; Gillet M.

Depletion of glutathione - a possible mechanism in galactosamine-induced liver injury
pp. 157-157(1)
Authors: Stojanovic I.; Pavlovic D.; Koracevic D.; Bjelakovic G.

Platelet serotonin (5HT) and MAO-B activity in a patient undergone OLT because of metastases from midgut carcinoid tumor
pp. 158-158(1)
Authors: Szalay F.; Borcsiczky D.; Meszaros Z.; Tekes K.; Dallos G.; Reti V.; Gorog D.; Perner F.

Detection of liver function with MEG-X test after liver transplantation
pp. 158-158(1)
Authors: Collavo T.; Corno V.; Risaliti A.; Bonfreschi V.; Colo F.; Donini A.; Pirisi M.; Anania G.; Bresadola F.

Cyclosporine associated acute cerebellar syndrome after liver transplantation
pp. 158-158(1)
Authors: Risaliti A.; Corno V.; Marcon G.; Pirisi M.; Soardo G.; Bulligan M.; Del Forno M.; Donini A.; Bresadola F.

Short-term prognosis of bacterial infection in hospitalized cirrhotic patients
pp. 159-159(1)
Authors: Borzio M.; Salerno F.; Angeli P.; Bissoli F.; Boccia S.; Colloredo G.; Corigliano P.; Fornaciari G.; Marenco G.; Pistara R.; Sangiovanni A.

Hemodynamic effects of vapreotide, a new somatostatin analogue, in patients with cirrhosis
pp. 159-159(1)
Authors: Gadano A.; Vachiery F.; Denie C.; Trombino C.; Moreau R.; Yong S.; Hillaire S.; Valla D.; Schneider P.; Lebrec D.

An antiviral alternative to IFN treatment in liver cirrhosis B and C
pp. 159-159(1)
Author: Popescu A.

Individual risk factors in progression towards cirrhosis in HCV patients
pp. 159-159(1)
Authors: Sebastiano D.; Margiotta M.; Goldoni E.; De Sanctis G.; Barbacini I.; D'Errico D.; Altavilla N.; Grimaldi F.; Chircu L.

M-like variants of alpha 1 antitrypsin deficiency in Sardinia
pp. 160-160(1)
Authors: Coni P.; Falchi A.; Liguori C.; Sanna G.; Loviselli A.; Lai E.; Callea F.; Faa G.

Noninvasive diagnosis of esophageal varices (EV) for the primary prevention
pp. 160-160(1)
Authors: Pilette C.; Oberti F.; Aube C.; Rousselet M.; Bedossa P.; Gallois Y.; Rifflet H.; Cales P.

Chronic hemodynamic and antifibrotic effects of vapreotide in cirrhotic rats
pp. 160-160(1)
Authors: Moal F.; Oberti F.; Pilette C.; Kaassis M.; Veal N.; Fort J.; Cales P.

Prothrombin index (PI) is an accurate marker of liver fibrosis or cirrhosis
pp. 160-160(1)
Authors: Pilette C.; Croquet V.; Oberti F.; Aube C.; Rousselet M.; Bedossa P.; Gallois Y.; Rifflet H.; Cales P.

Acute effects of somatostatin, octreotide or placebo in cirrhosis. A double blind controlled study
pp. 161-161(1)
Authors: Nishida H.; Giostra E.; Spahr L.; Mitamura K.; Hadengue A.

Effect of a non-steroidal anti-inflammatory drug (NSAID)-no donor (NO) on LPS-induced vascular hyporeactivity and expression of inducible no synthase (NOS II) in cirrhotic rats
pp. 161-161(1)
Authors: Lefilliatre P.; Sogni P.; Bertrand V.; Del Soldato P.; Pateron D.; Moreau R.; Lebrec D.

Alterations in peripheral hemodynamics in cirrhosis: are they related to methodology?
pp. 161-161(1)
Authors: Sacerdoti D.; Bombonato G.C.; Finucci G.F.; Favaro A.; Spadaro L.; Bolognesi M.; Casiglia E.; Pavan L.; Biasin R.; Ginocchio G.; Onesto C.; Gatta A.

Metalloendopeptidase EC3.4.24.15 and not angiotensin-converting enzyme (ACE) is the main liver bradykinin-inactivating enzyme
pp. 161-161(1)
Authors: Molina H.; Carmona A.; Kouyoumdjian M.; Juliano L.; Borges D.

CCl₄-induced liver inflammation and necrosis in mice lacking Tenascin-C
pp. 162-162(1)
Authors: Schuppan D.; Boigk G.; Ruhl M.; Herbst H.; Cho J.J.; Riecken E.O.; Fassler R.

Interaction between bolus and infusion of octreotide in portal hypertensive rats
pp. 162-162(1)
Authors: Kaassis M.; Moal F.; Oberti F.; Veal N.; Cales P.

Renal and hemodynamic effects of blockers and nitrates in cirrhosis
pp. 162-162(1)
Authors: Vuillemin E.; Oberti F.; Pilette C.; Cales P.

Intestinal permeability in liver cirrhosis
pp. 162-162(1)
Authors: Ersoz G.; Aydin A.; Akarca U.S.; Erdem S.; Yuksel D.; Kumanlioglu K.

Estimation of portosystemic shunt volume after tips by intravascular ultrasound
pp. 163-163(1)
Authors: Plauth M.; Wruck U.; Romaniuk P.; Sha'ath B.; Brockmoller J.; Johne A.; Roske A.-E.; Schutz T.; Wermke W.; Lochs H.

Hepatocyte growth factor and the degree of liver failure in alcoholic liver cirrhosis patients
pp. 163-163(1)
Authors: Antoljak N.; Topic E.; Duvnjak M.; Vrkic N.; Zuntar I.

The portal hypertensive response to kinins in normal, inflamed or cirrhotic rats
pp. 163-163(1)
Authors: Loureiro-Silva M.; Molina H.; Borges D.

Arterial pression and cardiac frequency variability and assessment of baroreflex sensitivity in liver cirrhosis
pp. 164-164(1)
Authors: Gallo V.; Di Napoli A.; Riva P.; Sidoli L.; Bisbocci D.; Calva S.

Expression of insulin like growth factor (IGF-II) and of the IGF II receptor (IGF-IIR) in normal and cirrhotic human liver
pp. 164-164(1)
Authors: Sedlacek N.; Herbst H.; Hasilik A.; Neuhaus P.; Bechstein W.O.; Riecken E.O.; Schuppan D.

Endoscopic and ultrasound criteria predicting less development of portal-hypertensive gastropathy in hepatic cirrhosis
pp. 164-164(1)
Authors: Gheorghe C.; Gheorghe L.; Grigoruta S.; Oproiu A.

Hemodynamic changes after tips due to an increased cardiac preload?
pp. 164-164(1)
Authors: van Hoek B.; Bindels A.; van der Hoeven J.; Frohlich M.; Schultze Kool L.; Meinders A.

Total paracentesis does not impair nutritional status in cirrhotic patients with tense ascites
pp. 165-165(1)
Authors: Colombo M.; Pozzi M.; Pecci V.; Tomasoni F.; Gamba P.; Massironi S.; Capra M.; Cogliati M.; Mancia G.

Helicobacter pylori, hiperammonemia and subclinical portosystemic encephalopathy: effects of eradication
pp. 165-165(1)
Authors: Llach J.; Vasconez C.; Elizalde J.; Bordas J.; Gines A.; Mas A.; Pique J.; Teres J.

Anti-oxidant effects of colchicine
pp. 165-165(1)
Authors: Das D.; Pemberton P.; Burrows P.; Gordon C.; Smith A.; Warnes T.

Relationship between oxidative stress and autonomic neuropathy in liver cirrhosis
pp. 165-165(1)
Authors: Simoncini M.; Trevisani F.; Mainqua P.; Sica G.; Caraceni P.; De Notariis S.; Domenicali M.; Angelini G.R.; Guarnieri C.; Bernardi M.

Prospective assessment of the risk of bacteremia in cirrhotic patients undergoing colonoscopy
pp. 166-166(1)
Authors: Llach J.; Bordas J.; Gines A.; Elizalde J.; Sans M.; Mondelo F.; Rimola A.; Pique J.; Rodes J.

Does oxidative stress account for the extrahepatic complications of cirrhosis?
pp. 166-166(1)
Authors: Ljubuncic P.; Tanne Z.; Bomzon A.

The clearance of tissue-type plasminogen activator in inflamed and cirrhotic rats
pp. 166-166(1)
Authors: Nagaoka M.; Kouyoumdjian M.; Borges D.

Hemodynamic changes following embolization of the splenic artery (ESA) in advanced liver cirrhosis
pp. 166-166(1)
Authors: Boulanov K.; Chooklin S.

Insulin-like growth factor-I serum and liver concentrations in rats with porta-caval shunt
pp. 167-167(1)
Authors: Radosavljevic T.; Sikic B.; Nikolic J.A.; Petakov M.; Todorovic V.

Evolution of portal hypertensive gastropathy(PHG) afterendoscopic ligation of esophageal varices(ELV)
pp. 167-167(1)
Authors: Goldis A.; Vernic C.; Strain R.

Hypertensive gastropathy in cirrhotic patients with portal hypertension
pp. 167-167(1)
Authors: Bibolli I.; Basho J.; Resuli B.

Prognostic influence of hepatic involvement in patients with cardiac cirrhosis
pp. 167-167(1)
Authors: Andronescu D.; Greceanu I.M.; Fierginteanu-Braticevici C.; Olteanu D.

Coagulation disorders in patients with liver cirrhosis
pp. 168-168(1)
Authors: Stojanov D.B.; Bjelakovic G.; Nagorni A.; Tasic T.

Cytokines and nitric oxide derivatives (NO) after variceal bleeding: correlation with portal and splenic blood flows
pp. 168-168(1)
Authors: Chagneau C.; Kaffy F.; Borderie C.; Lecron J.C.; Millet C.; Wahl A.; Piriou M.; Tailboux L.; Beauchant M.; Silvain C.

Diagnosis of portal vein thrombosis
pp. 168-168(1)
Authors: Szantova M.; Kupcova V.

Helicobacter pylori infection in alcoholic and virus induced cirrhosis
pp. 168-168(1)
Authors: Krstic M.; Tomic D.; Jankovic G.; Jesic R.; Milinic N.; Milosavljevic T.; Pavlovic A.; Grbic R.

Helicobacter pylori and hepatic encephalopathy
pp. 169-169(1)
Authors: Vcev A.; Horvat D.; Pezerovic D.; Stimac D.; Vceva A.

Diagnosis of portal hypertension
pp. 169-169(1)
Authors: Szantova M.; Kupcova V.

Prophylaxis with norfloxacin of spontaneous bacterial peritonitis in cirrhotic patients
pp. 169-169(1)
Authors: Braticevici C.F.; Chirila R.; Braticevici B.

Spontaneous bacterial peritonitis(SBP) in liver cirrhosis
pp. 169-169(1)
Authors: Ditoiu A.V.; Motoi O.

The coagulation disorders in liver cirrhosis
pp. 170-170(1)
Authors: Babameto A.; Basho J.; Resuli B.

The role of splenectomy and embolization of the splenic artery (ESA) in the management of the complicated liver cirrhosis
pp. 170-170(1)
Authors: Chooklin S.; Boulanov K.

Clinical aspects of liver cirrhosis - evaluation of liver function by measuring the lidocaine metabolite formation (MEGX)
pp. 170-170(1)
Authors: Kupcova V.; Turecky L.; Szantova M.; Schmidtova K.

The cytology of the cirrhotic and malignant ascitic fluid
pp. 170-170(1)
Authors: Bjelakovic G.; Katic V.; Tasic T.; Dakovic M.

Biochemical alterations of cholesterol and hemostatic factors in cirrhotic
pp. 171-171(1)
Authors: Zaganjori R.; Beqari N.; Buzo S.; Basho J.; Bibolli I.

Enzimatic and electrophoretic alterations in cirrhotic patients
pp. 171-171(1)
Authors: Buzo S.; Beqari N.; Zaganjori R.; Basho J.; Bibolli I.

The spontaneous bacterial ascites-peritonitis and bacterial translocation on patients with the liver cirrhosis
pp. 171-171(1)
Authors: Perejaslov A.; Chooklin S.

The interaction between the cation-binding site and iron in oxidative modification of 5'-nucleotidase
pp. 172-172(1)
Authors: Kocic G.; Pavlovic D.; Vlahovic P.; Kocic R.; Jevtovic T.; Stojanovic I.

Hepatic antifibrotic effect of superoxide dismutase (SOD) in murine Schistosomiasis
pp. 172-172(1)
Authors: Guerret S.; Ricard-blum S.; Dugas B.; Postaire E.; Hartmann D.; Chevallier M.; Chossegros P.

Vascular endothelial growth factor (VEGF) promotes parenchymal liver cell growth in vivo
pp. 172-172(1)
Authors: Baruch Y.; Krasik A.; Shoshany G.; Shenkar L.; Assy N.; Paizi M.; Kraizer Y.; Spira G.

Measurement of TIMP-1 in serum by the bayer immuno 1(R) mirrors hepatic fibrogenesis
pp. 173-173(1)
Authors: Gehrmann M.; Schuppan D.; Oesterling C.; Ropers T.; Gillner D.; Jung K.

Circulating metalloproteinases and their tissue inhibitors in alcoholic liver disease. Relationship to liver fibrosis
pp. 173-173(1)
Authors: Gimenez A.; Gasso M.; Pares A.; Caballeria J.; Deulofeu R.; Roman J.; Caballeria L.; Rodes J.

Common bile duct ligation: induction of cholangiocyte prolactin receptor manifestation insensitive to hormonal regulation
pp. 173-173(1)
Authors: Smirnova O.V.; Petraschuk O.M.; Orlova A.N.

Levels of IL-2 AND IL-2R in chronic liverdisease: their role in viral infection and alcohol
pp. 173-173(1)
Authors: Macedo G.; Pinto T.; Ramos J.P.; Sarmento J.A.; Vale A.M.; Candeias J.; Ribeiro T.

The effect of colchicine in experimental liver fibrosis
pp. 174-174(1)
Authors: Resuli B.; Braho S.; Haxhihyseni E.; Leskoviku S.

Serum markers of fibrogenesis and collagenolysis in patients with chronic liver disease
pp. 174-174(1)
Authors: Gasso M.; Gimenez A.; Pares A.; Deulofeu R.; Roman J.; Caballeria L.; Caballeria J.; Rodes J.

Tissue inhibitors of metalloproteinases serum and liver in patients with chronic hepatitis C
pp. 174-174(1)
Authors: Boker K.H.W.; Pehle B.; Steinmetz C.; Breitenstein K.; Lichtinghagen R.

Changes of liver extracellular matrix structure in chronic delta hepatitis
pp. 174-174(1)
Authors: Aliev B.; Hodjaev S.

Unsaturated bile acids in the urine of patients with hepatocellular neoplasia
pp. 175-175(1)
Authors: Marin J.J.G.; Badia M.D.; Luengo N.; Monte M.J.; Jimenez F.; Serrano M.A.; El-Mir M.Y.

Intrahepatic distribution of heat shock proteins 27 and 70 during rat liver injury and regeneration induced by thioacetamide
pp. 175-175(1)
Authors: Theocharis S.; Kouraklis G.; Margeli A.; Skaltsas S.; Kittas C.

Hepatocyte proliferative index correlates with the risk of developing HCC in cirrhotics
pp. 175-175(1)
Authors: Sangiovanni A.; Colombo E.; Radaelli F.; Terreni N.; Spinzi G.; Casiraghi A.; Ceriani R.; Prada A.; Tavani E.; Minoli G.

TGF1 and apoptosis in human hepatocellular carcinoma and focal nodular hyperplasia
pp. 175-175(1)
Authors: Lotz G.; Nagy P.; Patonai A.; Kiss A.; Nemes B.; Szalay F.; Schaff Z.

Analysis of TGF-/EGFR, HGF/C-MET, TGF--RII and P53 expression in human hepatocellular carcinomas
pp. 176-176(1)
Authors: Kiss A.; Bogi K.; Schaff Z.; Thorgeirsson S.S.

Evaluation of albumin-migrating gamma-glutamyltransferase band in the treatment of hepatocellular carcinoma (HCC) by percutaneous ethanol injection (PEI). Preliminary report
pp. 176-176(1)
Authors: Pompili M.; Addolorato G.; Zuppi C.; Lorenzelli G.; Riccardi L.; Rossi C.; Pignataro F.; Cedrone A.; Rapaccini G.; Gasbarrini G.

Desialylated sex hormone-binding globulin (D-SHBG) in chronic liver diseases: a possible vector of sex steroids in hepatocytes
pp. 176-176(1)
Authors: Rakotomalala L.; Pontet M.; Ganne-Carrie N.; Vaysse J.; Christidis C.; Trinchet J.; Beaugrand M.

Palliative therapy of advanced hepatocellular carcinoma - doxorubicin and tamoxifen vs. tamoxifen
pp. 176-176(1)
Authors: Schachschal G.; Lochs H.; Plauth M.

Isolating apoptotic related dnas from human hepatoma cell line treated with adriamycin
pp. 177-177(1)
Authors: Wang W.; Yang F.; Ma Y.; Zhang X.

Transforming growth factor-beta1 and its receptors in invading and expanding types of human hepatocellular carcinoma
pp. 177-177(1)
Authors: Baer H.U.; Abou-Shady M.; Friess H.; Zimmermann A.; Buchler M.W.

Apoptosis and cytoproliferation in chronic HCV-related hepatitis
pp. 177-177(1)
Authors: Farinati F.; Cardin R.; D'Errico A.; Grigioni W.; Fiorentino M.; Floreani A.; Naccarato R.

Fucosylation ratio of alpha fetoprotein. Increased accuracy on hepatocellular carcinoma
pp. 177-177(1)
Authors: Peneda J.; Fonseca A.; Calinas F.; Bentes T.; Coimbra J.; Sampaio M.; Godinho R.; Medeiros I.; Santo C.E.; Oliveira M.

8-hydroxy-2'-deoxyguanosine (OHdG) DNA adduct formation is correlated to the inflammatory infiltration in hepatocellular carcinoma (HCC) and peritumor tissue
pp. 178-178(1)
Authors: Jungst C.; Gehrke R.; Schirmacher P.; Schramel P.; Grutzner U.; Schmitz V.; Ramakers J.; Sauerbruch T.; Caselmann W.H.

Liver tumor biopsy (LTB) of hepatocellular carcinoma (HCC): a potential risk ?
pp. 178-178(1)
Authors: Szostak-Talbodec N.; Danze P.; Roumilhac D.; Formstecher P.; Paris J.

Risk factors for hepatocellular carcinoma (HCC) in HCV cirrhotic patients undergoing liver transplantation
pp. 178-178(1)
Authors: Messner M.; Turlin B.; Moirand R.; Meunier B.; Launois B.; Brissot P.

Malnutrition in patients with HCC - role of food intake and substrate utilisation
pp. 178-178(1)
Authors: Schutz T.; Roske A.-E.; Lehmann A.-C.; Lochs H.; Plauth M.

Liver dysplasia in transplanted patients due HCV related cirrhosis with or without hepatocellular carcinoma (HCC): study of liver explants
pp. 179-179(1)
Authors: Salinero E.; Alvarez R.; Duran F.; Piqueras B.; Santos L.; de Diego A.; Salcedo M.; Alvarez E.; Clemente G.

Assessment of alpha-fetoprotein variants in patients with hepatocellular carcinoma and liver metastatic tumors
pp. 179-179(1)
Authors: Kupcova V.; Turecky L.; Szantova M.; Uhlikova E.

Prospective controlled trial of tamoxifen versus tamoxifen associated to beta-interferon in the treatment of advanced hepatocellular carcinoma
pp. 179-179(1)
Authors: Lorenzelli G.; Rapaccini G.; Sica G.; Pignataro G.; Cedrone A.; Valle D.; Sanalitro M.; Pompili M.; Gasbarrini G.

Can alpha-fetoprotein predict the recurrence and mortality of HCC patients treated by liver transplant?
pp. 179-179(1)
Authors: Castells L.; Vargas V.; Balsells J.; Margarit C.; Esteban R.; Guardia J.

Ornithine decarboxylase activity in acute and chronic CCl₄ - induced liver damage
pp. 180-180(1)
Authors: Antoniello S.; Auletta M.; Pardo F.

Antinuclear antibodies, marker of hepatocarcinogenesis in chronic liver disease?
pp. 180-180(1)
Authors: Buligescu L.; Cojocaru L.; Micu L.

Quantification of liver fibrosis in needle biopsy specimens by fractal analysis
pp. 181-181(1)
Authors: Grizzi F.; Dioguardi N.

Determination of minimal hepatitis C virus-specific inhibitory antisense oligodeoxynucleotides in an in vitro and a cellular system
pp. 181-181(1)
Authors: Serwe M.; Lehmann T.; Alt M.; Burgelt E.; Voosen B.; Sauerbruch T.; Caselmann W.H.

Identification of a novel HGBV-C/HGV subtype
pp. 181-181(1)
Authors: Lopez-Alcorocho J.M.; Castillo I.; Tomas J.F.; Carreno V.

Autoantibody prevalence in chronic hepatitis C patients treated with interferon alpha and isoprinosine
pp. 181-181(1)
Authors: Osna N.; Hagina E.; Silonova G.; Kuse V.; Viksna L.; Sochnev A.

Decorin expression and distribution in chronic hepatitis C
pp. 182-182(1)
Authors: Jarmay K.; Karacsony G.; Gallai M.; Nagy I.; Schaff Z.

Measuring serum HCV RNA in clinical samples : a specificity and sensitivity study
pp. 182-182(1)
Authors: Martinot M.; Martins-Amado V.; Marcellin P.

Hepatitis delta genotypes in chronic delta infection in the northeast of spain
pp. 182-182(1)
Authors: Buti M.; Jardi R.; Cotrina M.; Rodriguez F.; Castells J.; Quer J.; Esteban R.; Guardia J.

Difficulties in serological genotyping of HCV infection in patientswith porphyria cutanea tarda
pp. 182-182(1)
Authors: Antonov K.; Ivanova A.; Adjarov D.

Prevalence of HGV in patients with HCV-positive mixed cryoglobulinemia
pp. 183-183(1)
Authors: Crovatto M.; Mazzaro C.; Santini G.F.; Faelli A.; Baracetti S.; Fanni M.; Mazzoran L.; Zorat F.; Pozzato G.

Biodistribution and pharmacokinetics of antisense phosphorothioate oligodeoxynucleotide in mice
pp. 183-183(1)
Authors: Yao Z.Q.; Huang A.Q.; Yap S.H.

Hepatitis G virus co-infection in anti-HCV positive long-timehemodialysed patients
pp. 183-183(1)
Authors: Stanczak J.J.; Tobolewska E.; Baran J.; Podlasin R.; Horban A.

Hepatitis G virus in patient's with Behcet's syndrome
pp. 183-183(1)
Authors: Kip Ulgen S.; Basgul S.; Fresko I.; Geyik G.; Demiralp E.; Direskeneli H.; Sayhan N.; Sonsuz A.; Gul A.; Aral O.; Yazici H.; Tozun N.; Kalayci C.

The importance of hepatic expression of ICAM-1, HLA-DR, LFA-1 and HBcAg in chronic hepatitis B virus infection
pp. 184-184(1)
Authors: Djokic M.; Bojic I.; Colic M.; Dimitrijevic J.; Vucevic D.; Begovic V.

Absence of GBV-A and GBV-B sequences in human sera
pp. 184-184(1)
Authors: Madejon A.; Fogeda M.; Tomas J.F.; Castillo I.; Carreno V.

Retreatment of patients with hcv-positive mixed cryoglobulinemia (MC) who previously failed 12 months interferon therapy
pp. 184-184(1)
Authors: Mazzaro C.; Colle R.; Lacchin T.; Carniello G.; Donada C.; Rizzo W.; Baracetti S.; Gregorutti M.; Faelli A.; Crovatto M.; Santini G.F.; Fanni M.; Zorat F.; Pozzato G.

Ultrastructural study of liver biopsies in chronic hepatitis C (CHC) patients related to genotype 3/A
pp. 184-184(1)
Authors: Asti A.; Ferrari L.; Balduzzi C.; Barbieri F.; Barbarini G.; Rinaldi A.; Belloni G.

Hepatitis C virus (HCV) in blood donors: diagnosis by the reverse transcriptase-polymerase chain reaction method (RT-PCR)
pp. 185-185(1)
Authors: Goncales N.S.L.; Escanhola C.A.; Vassallo J.; Goncales F.L.; Costa F.F.

Autoantibody prevalence in children with liver disease due to chronic hepatitis C virus infection
pp. 186-186(1)
Authors: Gregorio G.; Pensati P.; Iorio R.; Vegnente A.; Mieli-Vergani G.; Vergani D.

GBV-C/HGV infection: a favourable prognostic factor in HIV infected patients?
pp. 186-186(1)
Authors: Heringlake S.; Ockenga J.; Tillmann H.L.; Trautwein C.; Meissner D.; Stoll M.; Schmidt R.E.; Manns M.P.

A community based survey of HCV infection in the general population of a Greek Island
pp. 186-186(1)
Authors: Goritsas C.; Plerou I.; Agaliotis S.; Spinthaki R.; Mimidis K.; Velissaris D.; Lazarou N.; Lampropoulou-Karatza C.

Thyroid tests in patients with hepatitis C before and during interferon (IFN) therapy
pp. 186-186(1)
Authors: Rossini A.; Biasi L.; Rossi M.; Cariani E.; Radaeli E.

HCV-RNA minus-strand in PBMC in patients undergoing chronic hemodialysis
pp. 187-187(1)
Authors: Mazur W.; Machniak M.; Mazurek U.; Miasko A.; Wilczok T.; Bulanowski Z.; Petelenz M.; Gonciarz Z.

Importance of nucleolar changes of hepatocytes in evaluation of hepatitis C virus infection activity
pp. 187-187(1)
Authors: Nozic D.; Skaro-Milic A.; Dimitrijevic J.; Bojic I.; Glisic S.

Phagocytic activity of granylocytes in chronic hepatitis type B and C and the effect of treatment with interferon alpha (intron A)
pp. 187-187(1)
Authors: Flieger J.; Bolewska B.; Juszczyk J.

Changing prevalence of virus C genotypes according to age of patients and route of infection
pp. 187-187(1)
Authors: Giannini E.; Fasoli A.; Caglieris S.; Botta F.; Icardi G.C.; Celle G.; Testa R.

Influence of GB virus-C/hepatitis G virus infection on the long term course of chronic hepatitis B
pp. 188-188(1)
Authors: Fattovich G.; Ribero M.; Favarato S.; Azzario F.; Donato F.; Giustina G.; Fasola M.; Pantalena M.; Portera G.; Corrocher R.; Tagger A.

Natural -interferon retreatment in chronic hepatitis C
pp. 188-188(1)
Authors: Vandelli C.; Renzo F.; Lovato E.; Tisminetzky S.; Baralle F.; Ventura E.

Interferon retreatment in patients with chronic hepatitis C
pp. 188-188(1)
Authors: Vandelli C.; Renzo F.; Baralle F.; Lovato E.; Tisminetzky S.; Ventura E.

Impact of antihiv tritherapy on HCV infection: biological and virological analysis
pp. 188-188(1)
Authors: Zylberberg H.; Chaix M.-L.; Rabian C.; Berthelot P.; Rouzioux C.; Viard J.-P.; Brechot C.; Pol S.

The genotypes of HCV in the general population of a northern Italian town
pp. 189-189(1)
Authors: Maggi G.; Armitano S.; Cairo M.; Galvani G.; Gola D.; Marmondi E.; Passarella S.; Perricone G.; Posca M.; Vegezzi P.; Vergani C.; De Leo G.

Gastric malt lymphoma : a pathogenetic role of hepatitis C virus (HCV)?
pp. 189-189(1)
Authors: Tkoub E.M.; Haioun C.; Pawlotsky J.M.; Dhumeaux D.; Delchier J.C.

Do non responder to IFN chronic hepatitis (CHC) patients improve histological lesions ?
pp. 189-189(1)
Authors: Leroy V.; Barnoud R.; de Traversay C.; Hartmann J.; Baud M.; Maynard M.; Zarski J.

Epidemiological features of chronic hcv infection in Italian children
pp. 189-189(1)
Authors: Bortolotti F.; Resti M.; Giacchino R.; Crivellaro C.; Zancan L.; Gussetti N.; Azzari C.; Faggion S.

Efficacy of a third generation pre-S1/-S2-containing HBV vaccine (Hepagene&unknown;) as immunotherapy for HBeAG positive chronic hepatitis
pp. 190-190(1)
Authors: Carman W.; Tucker T.; Song E.; Hawarden D.; Kirsch R.; Van Deursen F.; O'Donnell B.; Maloney E.; Williams A.

A plastic anemia-associated hepatitis successfully treated by bone marrow transplantation
pp. 190-190(1)
Authors: Safadi R.; Or R.; Ilan Y.; Klein A.; Shouval D.; Galun E.

Efficacy and safety of interferon therapy in patients with porphyria cutanea tarda (PCT) and chronic hepatitis C
pp. 190-190(1)
Authors: Fernandez I.; Castellano G.; de Salamanca R.; Domingo M.; Colina F.; Fuertes A.; Canga F.; Munoz R.; Solis J.

Peripheral blood lymphocyte subsets in chronic type C hepatitis patients treated with IFN
pp. 190-190(1)
Authors: Stalke P.; Witczak K.; Korczak-Rogon A.; Kiszkis H.; Smiatacz T.

Recombinant vs leucocytic interferon in the treatment of HCV chronic liver disease: final report of a randomized controlled trial
pp. 191-191(1)
Authors: Ascione A.; De Luca M.; Guardascione M.; Canestrini C.; Galeota Lanza A.; Di Costanzo G.G.; Amitrano L.; Picciotto F.; Caporaso N.; Morisco F.; Tuccillo C.

Monitoring HCV-RNA levels during the first month of treatment identifies primary responders to interferon
pp. 191-191(1)
Authors: Colombatto P.; Baldi M.; Randone A.; Oliveri F.; Aragon U.R.; Maina A.M.; Bonino F.; Brunetto M.R.

HCV and HBV infection in hemodialysis (HD) patients: risk factors for liver disease (LD) after renal transplantation (RTx)
pp. 191-191(1)
Authors: Barbieri V.; Marchini F.; Floreani A.; Rigotti P.; Pontisso P.; Cecchetto A.; Fagiuoli S.; Naccarato R.; Burra P.

-interferon treatment in thalassemia major patients with chronic hepatitis C and liver iron overload
pp. 191-191(1)
Authors: Clemente M.; Balloi R.; Muroni P.; Dessi C.; Cornacchia G.; De Virgiliis S.

Treatment of chronic hepatitis C with -interferon plus ofloxacin in patients not responding to -interferon alone
pp. 192-192(1)
Authors: Negro F.; Male P.-J.; Giostra E.; Rubbia-Brandt L.; Perrin L.; Hadengue A.

Thyroid abnormalities before and during treatment in patients with chronic hepatitis B or C
pp. 192-192(1)
Authors: Rigopoulou E.; Pyrsopoulos N.; Bamias G.; Demertzi E.; Mitsopoulou A.; Valsami I.; Tsagaris M.; Papafragas V.; Tsantoulas D.

Prospective study of the incidence of post-transfusion hepatitis (PTH) in high risk new-born babyes (NB)
pp. 192-192(1)
Authors: Ruiz-Extremera A.; Rey M.; Torres C.; Munoz de Rueda P.; Carmona I.; Quintero D.; Palacios A.; Salmeron J.

Prevalence of hepatic iron overload (HIO) in chronic hepatitis C (CHC)and B (CHB) and its relationship to liver injury and response to IFN
pp. 192-192(1)
Authors: Adinolfi L.; Pasquale G.; Mormone G.; Tonziello A.; Bellopede P.; Gambardella M.; Ragone E.; Bellomo P.; Lettieri A.; Ruggiero G.

Combination therapy with ribavirin and interferon in naive patients with chronic hepatitis C without virological response after two months of interferon therapy. Preliminary results
pp. 193-193(1)
Authors: Lunel F.; Cresta P.

Amantadina vs interferon in the treatment of chronic HCV infection
pp. 193-193(1)
Authors: Gerardi R.; Berardo C.; Marinelli R.M.A.; Delle Monache M.; Bacosi M.; Ricci G.L.

Intrafamily transmission of hepatitis C: a cross-sectional study in Central Italy
pp. 193-193(1)
Authors: Grieco A.; Berloco F.; Ficarra M.G.; Matera A.; Rapaccini G.L.; Pompei A.; Coletta D.; Vozzolo V.; Scarlini G.F.; Gasbarrini Fortuna G.; DeStefano G.; Gasbarrini G.

Combination therapy with interferon plus ribavirin in patients with mixed cryoglobulinaemia associated to HCV chronic hepatitis unresponsive to ALFA interferon
pp. 193-193(1)
Authors: Donada C.; Crucitti A.; Zanette G.; Piva S.; Tommasi L.; Mazzaro C.; Donadon V.

Virological and biochemical response to interferon administration are different in chronic hepatitis C
pp. 194-194(1)
Authors: Gimenez-Barcons M.; Ampurdanes S.; Tajahuerce A.; Sanchez-Tapias J.M.; Jimenez de Anta M.T.; Rodes J.; Saiz J.C.

The possibility to reduce hepatitis B morbidity through vaccination of adolescents
pp. 194-194(1)
Authors: Shakgildian I.V.; Mikhailov M.I.; Khukhlovich P.A.; Romanenko V.V.; Kuznetsova I.O.; Esaulkova A.Y.

Early antiviral response to alpha interferon therapy in patients with chronic hepatitis C. Relationship with genotype and dose of interferon
pp. 194-194(1)
Authors: Boyer N.; Martinot M.; Martins-Amado V.; Meyer P.; Pouteau M.; Mugnier J.; Erlinger S.; Benhamou J.; Marcellin P.

Anti hepatitis G E2 antibody detection and its relation to serum HGV-RNA in patients with clotting disorders
pp. 194-194(1)
Authors: Sheng L.; Soumillion A.; Peerlinck K.; Verslype C.; Schelstraete R.; Gyselinck F.; Emonds M.-P.; Hess G.; Vermylen J.; Desmyter J.; Yap S.H.

Different distribution of aminotrans-ferase values among healthy HCV carriers in relation to presence/absence of viremia
pp. 195-195(1)
Authors: Morisco F.; Tuccillo C.; Del Vecchio Blanco G.; Leone D.; De Dominicis R.; De Luise G.; Iasevoli P.; Sessa G.; Caporaso N.

Significance of serum IgM anti-HBc during interferon treatment in children with chronic hepatitis B virus infection
pp. 195-195(1)
Authors: Gregorio G.; Smith H.; Mieli-Vergani G.

Outcome of hepatitis B/D reinfection after liver transplantation under nucleoside analogue therapy
pp. 195-195(1)
Authors: Jaeckel E.; Tillmann H.; Krueger M.; Schmidt H.; Boeker K.; Trautwein C.; Flemming P.; Nashan B.; Bruns I.; Manns M.

Efficacy of lamivudine therapy in patients with HBV related liver disease
pp. 195-195(1)
Authors: Campo N.; Dardano G.; Caglieris S.; Mondello L.; Testa R.; Valente U.; Celle G.; Picciotto A.

Alpha-interferon therapy in hemophiliacs with chronic hepatitis C: a pilot study
pp. 196-196(1)
Authors: Verucchi G.; Attard L.; Guzzo F.; Rodorigo G.; Mori F.; DeRosa V.; Chiodo F.

Detection of HGV RNA in liver biopsies without serum HGV RNA in chronic hepatitis C
pp. 196-196(1)
Authors: Belloni G.; Insolia R.; Mazzucco M.; Poma R.; Barbarini G.; Barbieri F.; Ferrari L.; Balduzzi C.

Low-dose, non-toxic IL-2 as therapy for HIV/HBV and HIV/HCV coinfection
pp. 196-196(1)
Authors: Schlaak J.F.; Radecke K.; Kaluza W.; Meyer zum Buschenfelde K.-H.; Gerken G.

Ribavirin interferon combination in patients with chronic hepatitis C non responders to interferon:
pp. 196-196(1)
Authors: Diago M.; Valeros M.; Lujan M.; Cors R.; Carbonell P.; Garcia V.; Zapater R.; Gonzalez C.

Retreatment of chronic hepatitis C with ribavirin and interferon alpha: a study in non-responding and relapsing group of patients
pp. 197-197(1)
Authors: Vucelic B.; Ostojic R.; Hrstic I.; Scukanec-Spoljar M.; Vince A.

Twelve month interferon (IFN)- therapy induces a similar sustained response in anti-HBe-positive and HBeAg-positive chronic hepatitis B patients
pp. 197-197(1)
Authors: Fernandez I.; Castellano G.; Manzano M.; Colina F.; Munoz R.; Canga F.; Fuertes A.; Solis J.

Hepatitis G virus infection: the first data on the prevalence of HGV-RNA in portuguese patients
pp. 197-197(1)
Authors: Carvalho A.; Martinho A.; Coimbra H.B.; Porto A.

Characteristics of chronic hepatitis C in a Portuguese end stage renal disease population.
pp. 197-197(1)
Authors: Lebre L.; Menezes-Oliveira C.; Nascimento C.; Barreto C.; Martins A.; Barata J.D.; Bruges M.; Cardoso C.; Boquinhas J.M.; Pais M.J.

Interferon plus Ribavirin vs interferon alone in HCV chronic liver disease non responder to a previous cycle of interferon alone
pp. 198-198(1)
Authors: Ascione A.; De Luca M.; Guardascione M.; Canestrini C.; Galeota Lanza A.; Astritto S.; D'Asero C.; Froio F.; Piergrossi P.

Effects of the Japanese herbal medicine ' sho-saiko-to ' (TJ-9) on activated TH2 function in circulating T lymphocytes of patients with HCV-positive chronic active hepatitis
pp. 198-198(1)
Authors: Yamashiki M.; Nishimura A.; Nobori T.

Lack of benefit of prolonging interferon therapy in patients with chronic hepatitis C without early response
pp. 198-198(1)
Authors: Pouteau M.; Martinot M.; Boyer N.; Erlinger S.; Marcellin P.

Response to interferon treatment in patients with chronic hepatitis and HCV/HGV coinfection
pp. 198-198(1)
Authors: Benetti G.P.; Ramella G.; Lazza M.; Corbellini A.; Vitaliani G.; Fasola M.; Portera G.; Ribero M.L.; Tagger A.

Transmission of hepatitis C virus in monozygotic twins. Case presentation
pp. 199-199(1)
Authors: Goncales F.L.; Angerami R.N.; Stucchi R.S.B.; Pavan M.H.P.; Nouer S.A.; Goncales N.S.L.

Chloroquine (CQ) can induce a biochemical response in patients with chronic hepatitis C
pp. 199-199(1)
Authors: Schuppan D.; Schopper H.; Oesterling C.; Somasundaram R.; Stoelzel U.; Boigk G.; Riecken E.O.

Amantadine for chronic hepatitis C
pp. 199-199(1)
Authors: Gross J.; Poterucha J.; Gossard A.; Lindor K.; Zein N.

Ribavirin and recombinant interferon-a 2B in patients with chronic HCV infection nonresponders or relapsed after monotherapy with interferon-a
pp. 199-199(1)
Authors: Antonov K.; Jelev D.; Krastev Z.

The preliminary results of the comparative efficacy of treatment with interferon alfa 2A and 2B in children with chronic hepatitis B
pp. 200-200(1)
Authors: Mozer-Lisewska I.; Kowala-Piaskowska A.; Figlerowicz M.; Sluzewski W.

^99mTc-hepida plasma clearance test in prognostic evaluation of chronic active hepatitis type B (CAHB)
pp. 200-200(1)
Authors: Bialkowska J.; Jablkowski M.; Kuydowicz J.; Bialobrzeski J.

Prevalence of secondary porphyrinuria in patients with chronic hepatitis C infection
pp. 200-200(1)
Authors: Vogeser M.; Jacob K.; Zachoval R.

Influence of IFN and ribavirine on ICAM-1 serum concentration in chronic C hepatitis treatment
pp. 200-200(1)
Authors: Pawlowska M.; Halota W.; Topczewska-Staubach E.

Prevalence of autonomic neuropathy in HCV-related mixed cryoglobulinemia
pp. 201-201(1)
Authors: Ambrosone L.; Cantillo A.; Sanges G.; Ugolini G.; Mennella M.; Ammendola A.; Di Iorio G.; Migliaresi S.

Iron status in chronic hepatitis C and response to treatment with interferon
pp. 201-201(1)
Authors: Calinas F.; Oliveira M.; Coimbra J.; Alves M.; Sampaio M.; Santo C.E.; Medeiros I.; Peneda J.

Outcome of acute hepatitis B and C
pp. 201-201(1)
Authors: Zarebska-Michaluk D.; Kryczka W.; Medynska J.; Dutkiewicz E.

End of therapy response in HCV chronic liver disease relapsers to IFN retreated with combination therapy (interferon + ribavirin)
pp. 201-201(1)
Authors: Ascione A.; De Luca M.; Guardascione M.; Canestrini C.; Lanza A.G.; Astritto S.; D'Asero C.; Froio F.; Piergrossi P.

Efficacy of vaccination against HBV in dialysed patients
pp. 202-202(1)
Authors: Urbanowicz W.; Wawrzynowicz-Syczewska M.; Boron A.

Immunohistochemistry of B and T cells and ultrastructural study of biopsies from patients affected by ''acute hepatitis'' induced by interferon-treatment in CALD
pp. 202-202(1)
Authors: Hassan G.; Serafini B.; Hassan C.; Rosali M.; Stefanini S.

Change of HBsAg-carriers structure in regions with high and middle endemity of hepatitis B
pp. 202-202(1)
Authors: Mikhailov M.I.; Drobenjuk G.A.; Obukhov J.V.; Isaeva O.; Zubov V.; Gavoronok S.V.; Maksimov S.V.

Alpha-interferon therapy in patients with HCV and HGV coinfection: changes in quantitative HCV and HGV RNA levels
pp. 202-202(1)
Authors: Ramella G.; Benetti G.P.; Merlini R.; Gucciardo E.; Masciadri C.; Fasola M.; Portera G.; Ribero M.L.; Tagger A.

Immunogenicity of a recombinant hepatitis B vaccine in children with down syndrome. A controlled study
pp. 203-203(1)
Authors: Lopes A.I.; Palba M.; Charlston J.; Barrades C.; Pedro M.; Sousa J.S.

Comparison of effectiveness of three different interferon (IFN) schedules in chronic hepatitis C
pp. 203-203(1)
Authors: Kanatakis S.; Aggelou A.; Koutsis D.; Moussionis A.; Karahalios G.

No influence of interferon treatment on serum bile acid in patients with chronic hepatitis C
pp. 203-203(1)
Authors: Bolewska B.; Flieger J.; Juszczyk J.

Intra familial transmission of hepatitis C virus in Egypt
pp. 203-203(1)
Authors: Abdel Ghaffar T.Y.; Kamel M.; EL Moselhy S.; Abdel Malek N.

Routine diagnostic tests for the detection and quantitation of hepatitis C virus RNA
pp. 204-204(1)
Authors: Soviero S.; Barmat S.; Cheng L.; Hasselbring K.; Hinchey M.; Isopi L.; Kazanecki C.; McDonald S.; Ost D.; Petersen D.; Turri S.; Xue Z.; Yang J.; Yoder A.; Gutekunst K.

Interferon treatment on the carbohydrate metabolism of patients with chronic hepatitis-C
pp. 204-204(1)
Authors: Nemesanszky E.; Pusztay M.; Csepregi A.

Amantadine and interferon treatment of chronic hepatitis C patients - preliminary analysis
pp. 204-204(1)
Authors: Ben-Ari Z.; Zemel R.; Kazatzker A.; Manhaim V.; Tur-Kaspa R.

Myocardial function in HGV chronic infection
pp. 204-204(1)
Authors: Taliani G.; Ciavarella G.; Lino S.; Malaguti U.; Calcagnini G.; Badolato M.; Osso A.; Furlan C.; Ferretti G.; De Bac C.

Iron status of patients with chronic hepatitis C
pp. 205-205(1)
Authors: Ivashkin V.T.; Lukina E.; Majevskaja M.; Levina A.; Sysojeva E.; Pavlov C.; Khoroshko N.D.; Frank G.A.

HCV infection in haemodialysed patients - epidemiological and clinical aspects
pp. 205-205(1)
Authors: Inglot M.; Zalewska M.; Berny U.; Gladysz A.; Zwolinska D.

An automated sample preparation method for HCV PCR
pp. 205-205(1)
Authors: Hildebrandt J.R.; Herron R.; Starron A.; Li Z.; Reitz E.; Niemiec T.; Fairchild M.; Young K.C.; Baechler G.; Decker A.; Logan K.; Rey W.

Elevated alanine aminotransferase (ALT) in blood donors: an assessment of the main causes and its relationship to the development of hepatitis
pp. 205-205(1)
Authors: Goncales F.L.; Stucchi R.S.B.; Papaiordanou P.O.; Pavan M.H.P.; Chiovitti M.C.; Escanhoela C.A.F.; Goncales N.S.L.; Pinho J.R.R.

The prevalence of ultrasound-detected abdominal lymphadenopathies in chronic viral hepatitis. Is there a relationship with the effectivness of -interferon therapy?
pp. 206-206(1)
Authors: Gheorghe L.; Gheorghe C.; Ionitta A.; Oproiu A.

HCV-serotypes and their morphological liver consequences in asymptomatic HCV infections in Poland
pp. 206-206(1)
Authors: Halota W.; Pawlowska M.; Stolarczyk J.

Pilot study of lamivudine in chronic hepatitis C virus infection
pp. 206-206(1)
Authors: Garson J.; Gilson R.; Whitby K.; Hawley S.; Atkins M.

Prevalennce of anti HAV in patients with chronic liver diseases
pp. 206-206(1)
Authors: Diago M.; Lujan M.; Tuset C.; Cors R.; Garcia V.; Valeros M.; Carbonell P.; Gimeno J.

Alcohol and chronic HBV, HCV infection on iron status
pp. 207-207(1)
Authors: Peneda J.; Fonseca A.; Neto D.

HGV RNA in acute non A-C hepatitis
pp. 207-207(1)
Authors: Grabarczyk P.; Kryczka W.; Brojer E.; Medynska J.; Kubicka J.

Changes in serum procollagen III peptid levels during interferon therapy for chronic viral hepatitis
pp. 207-207(1)
Authors: Horvath G.; Osztrogonacz H.; Tolvaj G.; Stotz G.; David K.

Pilot study on safety and efficacy of recombinant alfa2b interferon (IFN) for treatment of HCV liver cirrhosis
pp. 207-207(1)
Authors: Mazzoran L.; Tamaro G.; Mangiarotti M.A.; Fanni M.; Gregorutti M.; Zorat F.; Pozzato G.

A comparison of histological, biochemical and serological parameters in patients with chronic hepatitis B treated with interferon-alfa
pp. 208-208(1)
Authors: Janas-Skulina U.; Caban J.; Skulina D.; Szczepanski W.; Zejc-Bajsarowicz M.; Warunek W.; Librant-Suska M.

The effect of alpha - 2b - interferon on lipid profile of patients with chronic hepatitis
pp. 208-208(1)
Authors: Kanatakis S.; Petrogiannopoulos C.; Koutsis D.; Agelou A.; Zaharof A.; Moussionis A.

UDCA. Alternative treatment in distinct categories of patients with chronic hepatitis C
pp. 208-208(1)
Authors: Kanatakis S.; Koutsis D.; Aggelou A.; Moussionis A.; Dritsas S.

Viral factors predicting response to interferon alfa therapy in patients with chronic hepatitis C - follow-up of 87 cases
pp. 208-208(1)
Authors: Stanczak J.J.; Opoka-Kegler J.; Baran J.; Tobolewska E.; Horban A.

Chronic HBV infection. Immunomodulation with levamisole in viremic HBeAg minus and anti HBe positive patients
pp. 209-209(1)
Author: Krastev Z.

The benefits of interferon treatment in chronic viral hepatitis
pp. 209-209(1)
Authors: Bullgescu L.; Colocaru L.; Mihaila M.; Micu L.

Thymic hormones reduce replication of hepatitis B virus (HBV) in a course of treatment of chronic active hepatitis B (CAHB)
pp. 209-209(1)
Authors: Jablkowski M.; Sidorkiewic M.; Dabrowska-Bernstein B.K.; Bialkowska J.; Kuydowicz J.

Effects of IFN treatment of chronic type C hepatitis patients with regard to some prognostic factors
pp. 209-209(1)
Authors: Kiszkis H.; Witczak-Malinowska K.; Korczak-Rogon A.; Stalke P.; Stolarczyk J.

Ribavirin and interferon -alfa combined therapy in relapsed patients with chronic hepatitis C
pp. 210-210(1)
Authors: Lengyel G.; Balint T.; Feher J.

Predictors of a response to interferon alfa treatment in HBV and HCV related chronic hepatitis
pp. 210-210(1)
Authors: Kasztelan- Szczerbinska B.; Slomka M.; Daniluk J.; Lozowski C.T.; Szczerbinski M.

Preliminary results of treatment of chronic hepatitis C with recombinant interferon alfa
pp. 210-210(1)
Authors: Warunek W.; Zyrkowska-Bieda T.; Librant-Suska M.; Zejc-Bajsarowicz M.; Janas-Skulina U.; Skwara P.; Caban J.

Prevalence of hepatitis G virus (HGV) in cancer patients in Turkey
pp. 210-210(1)
Authors: Ozyilkan O.; Elgin Y.; Cakir S.; Bedir A.; Ozyilkan E.; Gunaydin M.

Low level of HBV-DNA is the most powerful predictive factor of better response to IFN- therapy in chronic hepatitis B
pp. 211-211(1)
Authors: Simon K.; Gladysz A.; Zalewska M.; Rotter K.; Dobracki W.; Glowacki A.; Inglot M.; Knysz B.; Machaj A.; Piszko P.

IFN- therapy patients with chronic hepatitis C in Poland -unsolved problems
pp. 211-211(1)
Authors: Simon K.; Gladysz A.

Additional laboratory criteria for acute and chronic hepatitis C diagnosis
pp. 211-211(1)
Authors: Mukomolov S.; Vasilieva E.; Sologub T.; Plotnikova V.

Is there any correlation between the dimensions of the spleen and theKnodell score in patients with chronic viral hepatitis?
pp. 211-211(1)
Authors: Sporea I.; Irimiea M.; Mocanu D.; Tudose N.; Strain R.

Hepatitis B and C virus infection in drug users. First Hungarian examination
pp. 212-212(1)
Authors: Osztrogonacz H.; Horvath G.; Tolvaj G.; Gerevich J.; David K.

The examination of anti-HCV or HBsAg seropositive blood donors and their family members
pp. 212-212(1)
Authors: Osztrogonacz H.; Horvath G.; Tolvaj G.; Stotz G.; David K.

Ribavirin and alpha-interferon in patients with chronic hepatitis C not responding to interferon alone
pp. 212-212(1)
Authors: Tripi S.; Di Gaetano G.; Cartabellotta F.; Vassallo R.; Soresi M.; Carroccio A.; Savi A.; Fulco M.; Montalto G.

Higher daily dose of alfa-interferon in non responder patients with chronic hepatitis C
pp. 212-212(1)
Authors: Artioli S.; Mignani E.; Guerra M.

Hepatitis G virus (HGV) infection in patients with chronic liver disease from Turkey
pp. 213-213(1)
Authors: Ozyilkan E.; Bedir A.; Bakan A.; Ozyilkan O.; Gunaydin M.

Clinical features of patients with chronic hepatitis C (HCV RNA-positive, HCV AB-negative)
pp. 213-213(1)
Authors: Ivashkin V.T.; Maevskaia M.V.; Lukina E.A.; Pavlov H.; Sysojeva E.; Frank G.A.

Acute hepatitis C:clinical features and outcomes
pp. 213-213(1)
Authors: Jemuovic L.; Delic D.; Boricic I.; Korac M.; Nikolic P.

The course of chronic HBV and HCV infection in children treated with interferon
pp. 213-213(1)
Authors: Rotter K.; Inglot M.; Gladysz A.; Simon K.

Clinical and morphologic features in HCV asymptomatic ''carriers''
pp. 214-214(1)
Authors: Zhdanov K.; Lobzin Y.; Mukomolov S.; Povzun S.; Chirsky V.; Plotnikova V.; Koshil O.; Korshunov P.

Suggestions for evaluating and using hepatitis C screening tests
pp. 214-214(1)
Authors: Lunel F.; Rosenheim M.; Duneton P.

Follow up and treatment of patients with chronic hepatitis C (1993-1997)
pp. 214-214(1)
Authors: Tornai; Posan E.; Szasz R.; Udvardy M.

Six months of interferon therapy-two different dosis- for chronic hepatitis C
pp. 214-214(1)
Authors: Ibranyi E.; Szentgyorgyi L.; Mihaly I.; Horanyi M.

Interferon alfa-2b therapy response in chronic hcv hepatitis patients at hungarian Home Defense Forces (HDF)
pp. 215-215(1)
Author: Rokusz L.

Interferon-alfa (IFN-a) in acute hepatitis C treatment
pp. 215-215(1)
Authors: Wawrzynowicz-Syczewska M.; Urbanowicz W.; Boron A.

ALT activity and necroinflamatory score for the patients with chronic hepatitis
pp. 215-215(1)
Authors: Mesihovic R.; Selimovic A.; Lacevic N.; Kesic V.; Filipovic A.

Evolutive peculiarities in chronic hepatitis C
pp. 215-215(1)
Authors: Buligescu L.; Mihaila M.; Cojocaru L.; Constantinescu S.; Micu L.

Insufficiency of a 6-month interferon-2b therapy in chronic hepatitis C
pp. 216-216(1)
Authors: Nagy I.; Velosy B.; Ozsvar Z.; Jarmay J.

Simultaneous administration of immunosuppressive drugs and or interferon
pp. 216-216(1)
Authors: Hassan G.; Marinucci G.; Hassan C.

The behaviour of alpha - fetoprotein (AFP) in benign liver disease
pp. 216-216(1)
Authors: Petrogiannopoulos C.; Flevaris C.; Lambropoulos L.; Zacharof A.K.; Vroulis D.J.; Sourvinou; Michalaki V.; Poulikakos J.

HCC patients treated with interferon in East Hungary
pp. 216-216(1)
Authors: Banyai T.; Martyin T.; Ozsvar Z.; Lonovics J.

Elimination of HBsAg and HBeAg after alpha-interferon treatment
pp. 217-217(1)
Authors: Dalmi L.; Weisz G.; Jancsik V.

ESWL of gallbladder stones: a focus on recurrence
pp. 218-218(1)
Authors: Carrilho-Ribeiro L.; Pinto-Correia A.; Carneiro de Moura M.

Regulatory Volume Decrease (RVD) inhibits NA⁺/H⁺ exchange in biliary epithelial cells
pp. 218-218(1)
Authors: Hubner C.; Kosa R.; Stremmel W.; Elsing C.

Circulating neutrophil elastase concentrations are increased in Primary Biliary Cirrhosis (PBC)
pp. 218-218(1)
Authors: Battista S.; Bar F.; Mengozzi G.; Cavalli G.; Giustetto D.; Rosina F.; Molino G.

Serum lipid spectrum in patients with calculous cholecystitis complicated by obstructive Jaundice
pp. 218-218(1)
Authors: Rusin I.; Selevich M.; Garelik P.; Lelevich V.

Hyper-responsiveness of neutrophils in severe acute alcoholic hepatitis
pp. 219-219(1)
Authors: Davalos M.; Clapperton M.; Phillips M.; O'Grady J.; Rolando N.

Effect of eating on total plasma radical-trapping antioxidant activity in patients with cirrhosis
pp. 219-219(1)
Authors: Pirisi M.; Federico E.; Fabris C.; Bortolotti N.; Falleti E.; Soardo G.; Mattiuzzo M.; Gonano F.; Bartoli E.

Ethanol potentiation of hypoxic hepatocyte injury: role of alterations of intracellular Na⁺ homeostasis
pp. 219-219(1)
Authors: Carini R.; De Cesaris M.G.; Parola M.; Albano E.

Interleukin 1 system in chronic ethanol addiction
pp. 219-219(1)
Authors: Gallo V.; Sidoli L.; Riva P.; Cantoni R.; Bisbocci D.

Increased hepatic degradation of amino acids (AA) during hemodialysis (HD) in pigs is followed by AA efflux from skeletal muscles
pp. 220-220(1)
Authors: Grofte T.; Ivarsen P.; Roelsgard K.; Greisen J.; Aagaard N.K.; Skjaerbaek C.; Hansen H.E.; Orskov H.; Vilstrup H.

Chronic ethanol administration affects oxydative stress by ischemia/reperfusion in rat liver
pp. 220-220(1)
Authors: Simoncini M.; Gasbarrini A.; Addolorato G.; Pasini P.; Nardo B.; Franceschi F.; De Luca A.; Vagni G.; Roda E.; Pola P.; Bernardi M.; Roda A.; Gasbarrini G.

Lipid peroxidation and antioxidative system in the blood of alcoholic liver disease patients
pp. 220-220(1)
Authors: Braticevici C.F.; Andronescu D.; Chirila R.; Greceanu I.; Mohora M.; Olteanu D.

Correlations between liver hystological structure and mitochondrial respiration in thioacetamide (TAA)-induced liver necroses
pp. 220-220(1)
Authors: Buko V.; Egorov A.; Karput S.; Prokopchik N.

Carbohydrate deficient transferrin and ketoisocaproic acid tests for alcohol abuse compared with liver histology and biochemical markers
pp. 221-221(1)
Authors: Minzer A.; Jenni C.; Hildebrand P.; Meyer-Wyss B.; Drewe J.; Beglinger C.; Sieber C.

Vagal system impairment in HIV-positive patients with chronic hepatitis C: has hepatic glutathione deficiency a pathogenetic role?
pp. 221-221(1)
Authors: Barbaro G.; Di lorenzo G.; Soldini M.; Bellomo G.; Belloni G.; Grisorio B.; Rizzo G.; Cadario F.; Barbarini G.

Neurological toxicity of alpha-interferon in HCV- or HBV-related immunological systemic disorders
pp. 221-221(1)
Authors: Ferri C.; La Civita L.; Monti M.; Longombardo G.; Fadda P.; Careccia G.; Gentilini P.; Pasero G.; Zignego A.

The role of hepatic tissue in changes of protein metabolism after endotoxin treatment in rats
pp. 221-221(1)
Authors: Holecek M.; Sprongl L.

The pharmacokinetics of lamivudine in patients with liver cirrhosis
pp. 222-222(1)
Authors: Horak J.; Johnson M.; Breuel P.

Antiradical and antioxidative effects of ursodeoxycholic acid in rat liver in vivo
pp. 222-222(1)
Authors: Lukivskaya O.; Maltsev A.; Karput S.; Zavodnik L.; Buko V.

New predictive factors for survival in abstaining alcoholic cirrhotics
pp. 222-222(1)
Author: Popescu A.

Clinical chemistry tests of hepatic function in obese newly-diagnosed non-insulin dependent diabetic patients on metformin monotherapy
pp. 222-222(1)
Authors: Kocic R.; Kocic G.; Pavlovic D.; Radenkovic S.; Mikic D.; Cvetkovic T.; Kocic B.

Potential biochemical markers of beneficial effect of L-arginine action
pp. 223-223(1)
Authors: Pavlovic D.; Nikolic J.; Kocic G.; Stojanovic I.; Jevtovic T.

Vascular responsiveness and liver viability during prolonged rat liver perfusion: the influence of the perfusate
pp. 223-223(1)
Authors: Yang W.; Benjamin I.S.; Alexander B.

Nonalcoholic steatohepatitis (NASH) as diagnostic problem
pp. 223-223(1)
Authors: Dutkiewicz E.; Kryczka W.; Urbaniak A.; Pabjan P.; Kubicka J.

Paracetamol induced acute liver injury in rabbits. Development of an experimental animal model
pp. 224-224(1)
Authors: Vagena M.; Dimitroulopoulos D.; Demonakou M.; Papalois A.; Bersos G.; Arvanitakis P.; Galanopoulou P.; Tsantoulas D.

Usefulness of CDT to identify alcohol abuse as cause of chronic liver disease
pp. 224-224(1)
Authors: Schachschal G.; Schonthal C.; Lochs H.; Plauth M.

Paracetamol hepatotoxicity in combination with ethanol in subjects after suicide attempt
pp. 224-224(1)
Authors: Zacharof A.K.; Petrogiannopoulos C.; Mauronasios K.; Papadakis E.; Zacharof H.

Nutritional assesment of patients with chronic hepatitis B and C
pp. 224-224(1)
Authors: Kulig G.; Boron A.; Sych Z.

Generation of reactive oxygen species during ethanol metabolism - role of aldehyde and xanthine oxidoreductases
pp. 225-225(1)
Authors: Maia L.; Mira L.; Freire A.; Manso C.

Liver iron in thalassemia patients receiving L1
pp. 225-225(1)
Authors: Mancosu M.G.; Callea F.; De Virgiliis S.; Galanello R.; Ambu R.; Sciot R.; Faa G.

HGV in patients with autoimmune hepatitis: anti-E2 antibodies and HGV-RNA in serum
pp. 226-226(1)
Authors: Tribl B.; Schoniger-Hekele M.; Petermann D.; Bakos S.; Penner E.; Muller C.

Interstitial lung fibrosis in patients with hepatitis C virus infection
pp. 226-226(1)
Authors: Ferri C.; La Civita L.; Fazzi P.; Monti M.; Longombardo G.; Careccia G.; Solfanelli S.; Porciello G.; Pasero G.; Gentilini P.; Zignego A.

Detection of human Mx protein in paraffin-wax embedded liver tissue
pp. 226-226(1)
Authors: Vassilev M.; Antonov K.; Michailov I.; Krastev Z.

Hepatic autoantigens in the autoimmune polyglandular syndrome type 1 and autoimmune hepatitis type 2
pp. 226-226(1)
Authors: Obermayer-Straub P.; Braun S.; Loges S.; Clemente M.G.; Luttig B.; Grams B.; Perheentupa J.; Manns M.P.